Preparation of human myometrium for term : the role of signalling associated proteins by Hatthachote, Panadda
PREPARATION OF HUNLAN MYOMETRIUM FOR TERM: 
THE ROLE OF SIGNALLING ASSOCIATED PROTEINS 
By 
Panadda Hafthachote 
NEWCASTLE UNIVERSITY LIBRARY 
---------------------------- 
099 13754 7 
---------------------------- 
K 
-1- 
6536 
A Thesis submitted for the Degree of Doctor of Philosophy 
University of Newcastle upon Tyne 
October 1999 
The study presented in this thesis is entirely the product of my own work. 
e", 01"-- q,., 
Aeo, 4ý, 
Panadda Hatthachote 
DEDICATION 
This thesis is dedicated to all the Thai people whose sacrifice has given me 
the opportunity to study abroad. I would especially like to thank the children 
from rural Thailand who have contributed to my education although they 
may not have received adequate schooling themselves. 
ACKNOWLEDGMENTS 
I would like to acknowledge all the patients who donated the myometrial samples 
required for this study. I thank the medical staff and nursing staff in the theatre and 
maternity units at the Royal Victoria Infirmary, Newcastle upon Tyne for their help in 
obtaining tissue samples. 
I wish to thank Professor James I. Gillespie and Professor William Dunlop, my 
supervisors, for his advice and guidance throughout my study. I am extremely grateful 
to Dr G. Nicholas Europe-Finner for his advice, support and patience while I was 
learning Western blot technique also his comments on my thesis. I would especially 
like to thank Mr. Richard Charlton for his help in immunohistochemical technique. 
There are those people who deserve my heartfelt gratitude: Dr Pauline Chambers, 
Dr Harry Otun, and Dr Lynne Hardy. Their advice and comment on my thesis have 
been invaluable. I thank you for everything. Warmest thanks also go to my ex- 
colleague, Dr Joanna Morgan, for her support and fiiendship during my study. Thanks 
to all of the staff in the Departments of Obstetrics and Gynaecology for all the love and 
friendship that I have been given. I will be forever grateful. 
Finally, I am indebted to the Thai Government and the Wellcome Trust for their 
financial support for this study. 
PUBLICATIONS 
Full Papers 
HATrHAcHoTF,. P., MoRGAN, J., DuNLoP, W., EuRoPE-FINNER, G. N. & GILLESPM J. I. 
(1998) Gestational changes in the levels of transforming growth factor-O I (TGFP I) and 
TGFP receptor types I and H in the human myometrium. Journal of Clinical 
Endocrinology andMetabolism 83,2987-2992. 
HATMACHOTE, P. & GILLESPIE J. I (1999) Complex interactions between sex steroids 
and cytokines in the human pregnant myometrium: evidence for an autocrine signalling 
system at term. EndocrinoloSy 140,2533-2540. 
Abstracts 
MoRGAN, J., AwAD, S. S., HA7rHAcHoTE. P., DuNLop, W. & GiLLEspiE, M. (1997) Up 
regulation of intracellular C2' signalling systems in the human pregnant myometrium: 
a role for TGFO 1. Acta Obstetricia Et Gymecologica Scandinavica 76, Suppl 167: 2,3 1. 
HATEHACHOTE. P., MORGAN, J., EUROPE-FI14NER, G. N. & GILLESPIE U. (1997) 
Changes in the expression of TGFO receptors and TGFO I in the human myometrium in 
late pregnancy. Joumal ofPhysiology 505P, P102-P103. 
HATmAmom P. & Guam J. I. (1999) The expression of IIL-1 receptor type I and 
IL-8 receptor type B in non-pregnant, non-labouring and labouring human myometrium. 
Journal of the Societyfor Gynaecologic Investigation 6, Suppl 1,226Aý 
HATTHAcHoTE. P. & GiLLEspiE J. 1. (1999) Interactions between cytokines and sex 
steroid hormones on TGFO 1 and TGFO receptor type I expression in human myometrial 
cells in vitro. Journal of the Socielyfor Gynaecologic Investigation 6, Suppl 1,226A 
HATMACHOTE. P. & GILLESPiE J. 1. (1999) The effects of raised cAW on the 
expression of signalling associated proteins in human myometrial smooth muscle cells 
in vitro. Jounial ofPhysioloSy 52 1 P, 53p. 
TABLE OF CONTENTS 
Chapter 1 INIRODUCTION 
1.1 The initiation of human labour 
1.1 Pre-term labour 
1.3 Quiescence and contractility in the pregnant myometrium 
I 
4 
5 
1.4 Regulation of myometrial function during pregnancy 6 
1.4.1 Role of contraction-associated proteins (CAPs) and myometrial activation 6 
1.4.2 Role of stimulatory agents and uterine stimulation I 
1.5 Regulation of contraction-associated proteins 14 
1.6 The contribution of cytokines to human pregnancy and parturition 16 
1.7 Cytokines and possible roles in normal pregnancy 18 
1.7.1 IL-1 and IL-1 receptors 18 
1.7.2 IL-8 and IL-8 receptors 19 
1.7.3 TGFP and TGFP receptors, 21 
1.8 Regulation of the levels of TGFP mRNA, TGFO secretion and activation 24 
1.8.1 Role of sex steroid hormones 24 
1.8.2 Role of cAMP 26 
1.8.3 Role of cytokines _27 
1.9 Choice of cytokines 28 
AIMS OF THE STUDY 29 
Chapter 2 METHODS 30 
2.1 Myometrial collection and ethical approval 30 
2.1.1 Myornetrial collection 30 
2.1.2 Ethical approval 31 
2.1.3 Removal of myometrium, from the uterus 31 
2.2 Preparation of human myometrial lysate _ 
31 
2.3 Immunohistochemistry 
2.3.1 Tissue section determination of TGFP receptors in human myometrial 
32 
smooth muscle 32 
2.3.2 Indirect immunostaining method 
2.4 Human myometrial cell culture techniques 
2.4.1 Isolation of human myornetrial smooth muscle cells 
32 
33 
33 
2.4.2 Cell passage 34 
2.4.3 Estimation of cell numbers 34 
2.4.4 Verification of myometrial. smooth muscle cell purity 
2.5 Treatment of cultured myometrial smooth muscle cells with Cytokines, 
steroid hormones, antibodies to cytokines and forskolin 
35 
38 
2.5.1 IL- I and IL-8 treatment and determination of TGFP I and TPRI expression 38 
2.5.2 TGFP I and IL-8 treatment and determination of TPRI and IL-8RB 39 
2.5.3 Sex steroid hormones treatment and determination of TGFP I and TPRI _39 
2.5.4 Cytokines and cytokines neutralising antibodies treatment and 
determination of TPRI 
2.5.5 Cytokincs and cytokines ncutralising antibodics treatmcnt and 
determination of cyclooxygenase-2 (COX-2) 
39 
40 
2.5.6 Forskolin treatment and determination of TGFP 1, TPRL c-Fos and c-Jun 40 
2.5.7 TGFP I treatment and determination of the G protein sub-units (Ga, and Ga, 1,2) 41 
2.6 Total protein assay 
_ _, 
41 
2.7 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western immunoblotting 42 
2.7.1 Protein sample preparation and gel electrophoresis 42 
2.7.2 Western Blotting: wet blotting system 42 
2.8 Immunoblotting and enhanced chemiluminescence system (ECL) 
. 
43 
2.9 Quantirication of immunoreactive bands 45 
2.10 TGF01 immunoassay 49 
2.10.1 Principle of the assay 49 
2.10.2 Sample preparation 51 
2.10.3 Activation procedures 51 
2.10.4 Preparation of standards 51 
2.10.5 Assay procedures 52 
2.10.6 Calculation of results 53 
2.11 Intracellular cAMP enzyme-immunoassay 53 
2.11.1 Sample preparation 53 
Appendix 2 145 
Appendix 3 147 
Appendix 4 148 
Appendix 5 149 
Introduction 
Chapter 1 
INTRODUCTION 
1.1 The initiation of human labour 
Much of our knowledge of parturition stems from " the progesterone block7 theory of 
labour, which was first proposed by Csapo in 1961 (see Greer, 1995). This theory suggests 
that there is a balance between myometrial. stimulants, including oestrogen and 
prostaglandins, and myometrial relaxants such as progesterone. During pregnancy this 
balance would be tipped in favour of progesterone but at parturition progesterone would 
fall and the balance tip in favour of myornetrial stimulants. Although this theory is true for 
parturition in sheep it is not the case for humans where there is no change in progesterone 
concentration at the time of labour. The endocrinological events associated with the 
initiation of parturition are much better understood in ovine than in human pregnancies (for 
review see Cunningham et aL 1997; Nathanielsz, 1999). Pioneering work of Liggins et al 
(1973) showed that in the sheep, the fetus was responsible for determining the timing of 
labour. It was demonstrated in these studies that fetal hypophysectomy or bilateral fetal 
adrenalectomy led to prolonged pregnancy. Contrarily, the infusion of adrenocorticotropin 
or cortisol into the sheep fetus earlier in pregnancy caused pre-term delivery. Thus, it is 
likely that fetal pituitary-adrenal axis is involved in the initiation of parturition in sheep 
The postulated role of the pituitary-adrenal. axis was strengthened by the demonstration 
of a rise in the concentration of cortisol in the fetal lamb circulation during the last 15 days 
of pregnancy (Liggins, 1973). Cortisol is produced by a cascade mechanism whereby the 
fetal hypothalamus releases corticotropin releasing factor (CRF) which in turn stimulates 
adrenocorticotrophic hormone (ACM in the pituitary. ACTH in turn stimulates adrenal 
cortisol production, which acts in the placenta to stimulate activity of 17-hydroxylase, 
which is required to convert progesterone to oestrogen (France et al. 1988). Thus, the 
balance between myometrial relaxation and myornetrial contraction is disturbed with a 
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reduction in progesterone and an increase in oestrogen. This change in placental steroid 
production thereby stimulates prostaglandin production via an increased activity of 
prostaglandin synthetase, gap junction formation, myornetrial. excitability and enhancement 
of uterine sensitivity to oxytocin. 
A role for the fetus in the initiation of primate parturition is also suggested by the 
findings of studies conducted in the rhesus monkey. It has been shown that fetal 
hypophysectomy can prolong gestation. If the fetus is removed, with the placenta left in 
situ, spontaneous delivery of the placenta is delayed (Nathanielsz et al, 1992). It can be 
interpreted from this study that the normal signal to deliver does not occur in the absence of 
the fetus. 
In the human fetus, the pituitary is necessary for adrenal maturation and steroidogenesis 
during the second half of pregnancy. However, there is little evidence of a role for fetal 
cortisol in the initiation of human labour. The major difference in endocrine events between 
these species is that the human placenta lacks 17-hydroxylase. Therefore, no changes in 
progesterone or oestrogen levels are found at the onset of labour (Liggins, 1983). Infusion 
of glucocorticoids to a human fetus failed to induce parturition (cited by Challis and Lye, 
1994) and furthermore mothers with an anencephalic fetuses went into spontaneous labour, 
although the length of gestation is more variable than in normal pregnancies (Lye, 1996). 
Despite the suggestion that the hypothalamo-pituitary-adrenal axis in the human fetus is 
unable to alter the steroid hormones at the placental level, there is evidence to support 
activation of this axis, which may play a central role in co-ordinating the transition from a 
state of quiescence to one of contraction. Maternal plasma levels of CRF increase 
dramatically during the third trimester (Grarnmatopoulos & Hillhouse, 1999). Furthermore, 
high levels of CRF have also been associated with the onset of pre-term labour (Frim. et aL 
1988). The source of CRF is not from fetus or maternal hypothalamus but from the placenta 
(Frim et al. 1988). It has been suggested that placental CRF can stimulate the fetal adrenal 
to produce cortisol and dihydro-epiandrosterone (DHEA)-sulphate, the latter being 
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converted to oestradiol by placental aromatase, and thus facilitate uterine activity (Greer, 
1995) 
It seems that there is evidence implicating a role for the pituitary-adrenal axis in human 
labour. However, human labour cannot be induced by cortisol administration and it is 
known that cortisol inhibits prostaglandin production by inhibiting the action of 
phospholipases (Blackwell et al. 1986). In addition, the observation from recent in vitro 
studies has shown that CRH did not affect myornetrial tension development (Simpkin et al. 
1999). Therefore, CRH is unlikely to play a major role in the onset of labour and in the 
control of myornetrial contractility. Other factors must therefore be involved in human 
parturition. It has been proposed that paracrine and autocrine mechanisms play a central 
role in the control of human parturition. The observations that locally acting prostaglandins; 
are involved in parturition and increased prostaglandins in the uterus support a role for the 
uterine environment in this process. It is also likely that there is no single factor able to 
initiate the onset of human labour, but rather a parturition cascade that remove the 
mechanisms maintaining uterine relaxation and recruits factors promoting uterine activity 
(Lye, 1996; Norwitz et al. 1999). These agents are called uterotonins, such as oxytocin and 
prostaglandin (see section 1.4.2). It is now recognised that the expression of these potent 
stimulants is increased in intra-uterine tissues during late pregnancy (Chibbar et al. 1993). 
Once the myornetrium. is prepared, endocrine, paracrine and autocrine factors then induce a 
switch from irregular contraction to co-ordinated contraction at term. 
Dysfimctional labour and disorders of parturition such as pre-term labour are a major 
cause of obstetric intervention. Thus, a better understanding of the physiological processes 
responsible for the onset and control of labour at term will advance our knowledge and 
improve our ability to develop better treatments to ensure a successful birth. 
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1.2 Pre-terfn Labour 
Pre-term labour, defined as labour before 37 weeks of gestation, occurs in up to 10 % 
of all births and is associated with 85 % of an perinatal complications and death (Norwitz et 
al. 1999). The costs consume more than one-third of health care expenditure during the first 
year of life. Moreover, additional expenditure for handicaps is necessary during the 
remainder of childhood for many infants. A wide spectrum of causes, including multiple 
gestation, uterine anomalies, infection, smoking, and demographic factors such as maternal 
age, race and poverty have been implicated in pre-term birth (Cunningham et al. 1997; 
Norwitz et al. 1999). Up to 30 % of pre-term labours result from intraamniotic infection 
(Romero & Mazor, 1988). Prostaglandins are considered to play a significant part in the 
onset and progression of labour both at term and pre-term (Thorburn & Challis, 1979). 
Bejar et al (1981) reported that many microorganisms produce phospholipase A2, 
which cleaves arachidonic acid within fetal membranes, thereby making free arachidonic 
acid available for prostaglandin synthesis. This may potentially initiate pre-term labour. It 
has been reported that introduction of bacterial endotoxin (lipopolysaccharides) in the 
amniotic fluid stimulates decidual cells to produce prostaglandin Mtchell et al. 1991b) and 
hence the early onset of labour. 
Pre-term parturition due to infection is thought to be initiated by endogenous secretory 
products, cytokines, resulting from monocyte activation. In many patients with infection, 
there are increased levels of cytokines including interleukin-1 (IL-1), IL-6 and tumour 
necrosis factor-a (TNF-a) in the amniotic fluid. These cytokines have been implicated in 
pre-term labour as increased prostaglandin synthesis has been observed in many cell types 
following treatment with these cytokines (for review see Mtchell et aL 1993b). A simplified 
mechanism of action by which bacteria induce pre-term labour is shown below. 
Prematurity and its consequences remain a major health problem. Although the 
mortality following pre-term birth has fallen the long-term consequences have not improved. 
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The prevention of pre-term labour has been very difficult because of poor understanding 
and the inability to predict myometrial contractility. Several biochemical markers such as 
activin, hihibin and fibronectin (Goldenberg et al. 1996; Petralglia, 1997) have been 
associated with pre-term labour. However, only fetal fibronectin in cervicovaginal 
secretions, which may reflect separation of the fetal membranes from the maternal decidua 
has been used successfully as a screening test for pre-term delivery (Goldenberg et al. 
1996). New drugs specific to the mechanism of contractility with fewer unacceptable side 
effects need to be developed to prevent labour or prolong pregnancy until a stage where the 
fetus has an increased chance of survival. 
Bacteria 
I Monocytesl 
Phospholipase A2 
Cytokines 
IL- 1, IL-6, TNF 
Prostaglandin E2 and F2, 
Pre-term labou7r 
1.3 Quiescence and contractility in the pregnant myometrfum 
During pregnancy, the myometrium. is maintained in a quiescent state by mechanisms, 
which limit myometrial contractility. These mechanisms include the maintenance of elevated 
plasma or myometrial levels of progesterone, the involvement of other hormones such as 
relaxh catecolamines and nitric oxide, and the expression of G-protein in the myometrium 
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(for reviews see Garfield & Yallampa4 1994; Lopez Bernal et aL 1995; Liu & Rebar, 
1999). Late in pregnancy, these mechanisms become less effective, meanwhile, other 
processes essential for initiation of contraction appear and become dominate. At which 
point during late pregnancy when these processes occur is unknown. However, it can be 
thought that sometime near term and before the onset of labour, these processes appear and 
the myometrium is prepared for effective contraction (Figure 1.1). 
By which processes myornetrial contraction is initiated in human are not well understood. It 
has been suggested that an increase in myornetrial activity and contractility during late 
pregnancy result from the myornetrium. being activated by synthesis and expression of a 
cassette of key proteins involving in contractile events. These proteins collectively were 
called contraction-associated proteins (CAPs) (Lye, 1994,1996). Once activated, the 
myornetrium. is capable of responding to the uterotonic agents such as oxytocin and 
prostaglandin (Lye, 1996). Then, the onset of labour begins. 
Term pregnancy 
Myometrial quiescence 
Myometrial 
Active 
preparation for labour labour 
Synthesis of CAPs Onset of labour 
Figure 1.1 Stages of pregnancy 
1.4 Regulation of myometrial function during pregnancy 
1.4.1 Role of contraction-associated proteins (CAPs) and myometrial activation 
Gap junctions, ion channels, uterotonin (e. g., oxytocin, prostaglandins) receptors and 
endothelin receptors are recognised to be CAPs which are present in the myometrium. at 
term (Boyle & Heshp, 1994; Chow & Lye, 1994; Mershon et al. 1994; Kimura et al. 1996; 
Wolff et al. 1996; Brodt-Eppley & Myatt, 1999). Awad et al (1997) has suggested that the 
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intracellular Ca. 2' release mechanism (RyR2), whose levels of gene expression increase in the 
pregnant myometrium during late gestation, is another example of a CAP. Once these 
proteins are expressed within the myometrial smooth muscle, the myometriurn is 
transformed from an overall state of quiescence to one primed for effective contraction. 
Gap junctions 
Gap junctions are channels composed of proteins called connexins (Willecke et aL 
199 1). Gap junctions provide pathways for the movement of ions, second messengers (C2' 
and inositol 1,4,5-trisphosphate UP3)) and for the flow of current between cells. Therefore, 
gap junctions enhance electrical coupling and facilitate the spread of excitation (Tabb & 
Garfield, 1992; Lopez Bernal, 1996). In the myometrium, a 43-kDa protein identified as 
comexin 43 (Cx43) is known to be the major component of a gap junction (Fishman et aL 
1990; Lang et al. 1991). 
Gap junctions are not detected in human myornetrium. in the early stages of pregnancy 
(Andersen et al. 1993) but are present in myornetrial tissues obtained from women in labour 
undergoing caesarean section compared with those not in labour at term (Garfield & 
Hayashi, 1981). The elevation of gap junction expression is found to be associated with an 
increase in Cx-43 mRNA and protein expression in the myornetrium. (Chow & Lye, 1994). 
Recently, it has been reported that levels of Cx-43 protein in the human myornetrium. at 
term are increased in upper segment myornetrial samples compared to those in lower 
segment (Sparey et al. 1999). In addition, Cx-43 levels in the myornetriurn during 
spontaneous labour are higher that that of non-labouring myornetrium. (Sparey et al. 1999). 
These results concur with the report by Chow and Lye (1994) indicating Cx-43 is increased 
in the human myometriurn toward term and with the onset of labour. It has been suggested 
that the differential expression of Cx-43 may underlie the propagation of contractions from 
the fundus to the cervix during the course of labour (Sparey et al. 1999). 
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Ca 2+ channels 
It is known that smooth muscle cells contract in response to a rise in [Caý']i and relax 
as the [C2']i fall. The level of [C2']i can be raised by an influx of C2' through the plasma 
membrane either via voltage-dependent C2+ channels (VOC) or through receptor-operated 
channel (ROC). C2+ can also be released from intracellular stores, for example the 
sarcoplasmic reticulum (SR) (Taylor & Traynor, 1995). 
Two types of VOC, T-type and dibydropyridine (DHP)-sensitive L-type C2' channels, 
have been described in the human myometriurn. (Young et aL 1993). It has been suggested 
by Batra (1989) that there is no difference in the binding of dihydropyridine between 
pregnant and non-pregnant myornetrium. However, in rat myornetrium., mRNA encoding 
the L-type C2+ channel increases during late pregnancy before term (Tezuka et aL 1995) 
and the spliced forms of the L-type channel increase during labour (Mershon et aL 1994). 
The SR is considered to be the most important store responsible for regulation of 
cytoplasmic C2' levels. The evidence so far suggests that there are two CP release 
channels on the SR: the IP3R-C2' release channel and the C2' induced-C2' release channel 
(RyR) (Berridge, 1993; Taylor & Traynor, 1995; Bezprozvanny & Ehrlich, 1996). At least 
five IP3R isoforms, encoded by different genes, exist on the SR in many cell types (Danoff et 
aL 1991; De Smedt et aL 1994). A 220-kDa IP3R type I isoform has been found in human 
myornetrium. (Yamada et aL 1994). 
A second type of SR CP release channel, the RyR, is activated when [C2+]i increases, 
and this produces the phenomenon of Caý'-induced C2+ release (CICR). Three genes 
encoding for RyRs have been identified; the RyRI gene encoding the skeletal muscle 
channel, the RyR2 gene present in cardiac muscle and RyR3 expressed in brain (Sorrentino 
& Volpe, 1993; Meissner, 1994). It has been thought that myometrium. probably does not 
express the RyRs, and hence CICR is unlikely. This conclusion was based on the 
observation that caffeine, the usual probe for the RyR-CICR mechanism, was unable to 
elevate [C2+]i in the myometrium. (Kanmura et aL 1988). It has been suggested that this 
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conclusion is incorrect because a novel type of CICR system, which is ryanodine-sensitive 
but caffeine-insensitive (RyR3), have been found in isolated human myometrial cells (Lynn 
et al. 1993). Continuing work has confirmed that RyR3 isoform is expressed in cultured 
myometrial smooth muscle cells and in both non-pregnant and pregnant human 
myometrium. Interestingly, RyR2 is found only in pregnant non-labouring myornetriurn 
(Awad et al. 1997). Based on these observations, the RyR2 system appears to be one of the 
contraction-associated proteins that is up-regulated in human myornetrium. at term. The 
functional significance of the RyR2 in human myornetriurn during pregnancy is not known. 
However, the upregulation of this gene may control [Caý']j levels and amplify the C2' 
transient needed to initiate contraction. Therefore, the myornetriurn can increase its ability 
to produce powerful contractions at term (Awad et aL 1997). 
Oxytocin receptor 
Both messenger ribonucleic acid (mRNA) and protein for oxytocin receptor are present 
in the non-pregnant myometrium at low levels. The expression levels of oxytocin receptors 
in the myometrium are found to increase significantly just before the onset of labour and 
reach the peak at parturition (Kimura et aL 1996). It has been found that the oxytocin 
receptors are distributed unevenly throughout the myornetriurn. The oxytocin receptors in 
the fundus, corpus and upper part of the lower segment are almost uniformly distributed. In 
the lower part of the lower segment, the levels of oxytocin receptor diminish and become 
very low in cervical tissue (Fuchs et aL 1984). It is well documented that uterine sensitivity 
to oxytocin gradually increases with advancing gestational age, accelerating during the last 
few days before the onset of labour (Husslein & Leitich, 1995). The rise in uterine 
responsiveness to oxytocin correlates with an increase in oxytocin receptor concentrations 
in the human myornetrium (Fuchs et aL 1984; Husslein & Leitich, 1995). Thus, the increase 
in oxytocin receptors allows oxytocin to trigger contractions without a rise in plasma levels 
of oxytocin. 
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Prostaglandin receptor 
There is substantial evidence to suggest the presence of multiple sub-types of PG 
receptors in human myometrium. (Hofinann et aL 1983; Adelantado et aL 1988; Matsumoto 
et aL 1997; Brodt-Eppley & Myatt, 1999). Upon binding to their ligands, different 
intracellular pathways are activated, depending on receptor subtypes. Pharmacologically, 
prostaglandin E (EPI, EP3),, prostaglandin F (FP) and thromboxane (TX) are linked to 
contractile events. EP2, EN, prostaglandin I and D (IP and DP) are associated with 
relaxation (Coleman et aL 1994). It has been reported that contractile receptors (EP3 and 
FP) are down regulated during pregnancy (Matsumoto et aL 1997). Recently, EP2 receptor 
mRNA expression has been found to increase during pregnancy and to decrease towards 
term, whereas FP receptor expression increases dramatically at term with labour (Brodt- 
Eppley & Myatt, 1999). Taken together, it can be suggested that down regulation of 
contractile prostaglandin receptors may influence the maintenance of uterine quiescence. In 
addition, an increase in contractile receptor concentrations in human myometriurn at term 
may mediate myornetrial contraction. As the concentration of EP receptors does not change 
during menstrual cycle (Hofinann et aL 1983; Adelantado et aL 1988), it is unlikely that EP 
receptors are controlled by ovarian steroids. 
Endothelin receptor 
It is generally accepted that endothelin is one of several receptors participating in the 
control of uterine activation. Receptors for endothelin type A (ETA) and type B (ETB) have 
been found in human myometrium. (Wolff et aL 1996). ETA receptor is involved in 
myornetrial. contractility by coupling to phospholipase C to generate IP3 and inducing an 
increase in [C2']i (Heluy et aL 1995). It has been shown that ETA receptor expression is 
higher in the upper than in the lower uterine segment and the ETB receptor is expressed in 
the opposite pattern (Wolff et aL 1996). ETA receptor mRNA in the upper uterine segment 
is significantly increased at term pregnancy, indicating a role of ETA receptor in parturition. 
The physiological function of the ETB receptor is unknown. However, it has been suggested 
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that this receptor may mediate myometrial relaxation as it can stimulate nitric oxide release 
in vitro (Yallampalli et aL 1993) 
1.4.2 Role of stimuIatory agents and uterine stimulation 
Oxytocin 
Oxytocin is a hormone secreted from the posterior pituitary gland. It has been 
discovered that oxytocin may be synthesised in uterine tissue itself (Lefebvre et al. 1992). 
Oxytocin stimulates myometrial contraction during labour by two parallel mechanisms: (1) 
by binding to cell membrane receptors coupled to G-proteins (Kimura et al. 1992), 
increasing [Caýjj via the inositide phospholipid pathway (Phaneuf et aL 1993) and (2) by 
stimulation through increasing PG release (Fuchs et aL 1982). Although oxytocin is used to 
induce labour and control postpartum haemorrhage, the precise role for oxytocin in the 
initiation of parturition remains unclear. This is because the concentration of oxytocin in 
maternal plasma does not change significantly before and during labour (Dawood et aL 
1978; Leake et al. 1981) and the progress of labour is not related to an increase in 
circulating oxytocin concentrations (Thornton et al. 1992). It has been argued that oxytocin 
receptor expression in the myometriurn may be so great that oxytocin action can occur with 
only small levels of circulating oxytocin. It is evident that the oxytocin receptors increase 
dramatically around the onset of labour (Fuchs et al. 1984; Kimura et al. 1992). Thus, the 
physiological importance of oxytocin in the initiation of labour could be triggered by an 
increase in myometrial sensitivity to oxytocin rather than the increase in circulating 
concentrations of this hormone. Another possibility might be that local production of 
oxytocin in the uterus might act in an autocrine or paracrine manner to stimulate 
contraction. This mechanism would diminish the responsibility of the circulating oxytocin. 
Oxytocin has been found to stimulate PG synthesis (Fuchs et al. 1982), thus, oxytocin may 
interact with other uterine stimulants to regulate contractility and improve myometrial 
contraction. In spite of the uncertain role for oxytocin in the initiation of labour, oxytocin 
remains an important hormone related to uterine function. 
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Prostaglandins (PGs) 
PGs have been proposed as a stimulus for myornetrial contraction during parturition in 
normal labour and in infection-induced pre-term labour (Kelly, 1994). The lines of evidence 
supporting PGs as being important in the initiation of spontaneous labour include the 
following: - PG levels in maternal plasma and amniotic fluid rise with labour progression and 
administration of prostaglandin E and F (PGE2 and PGF2,,, ) at any stage of pregnancy 
induces labour (Olson et aL 1995). In addition, successful pregnancy has been found to be 
associated with a rise in prostaglandin metabolites in the maternal plasma and in amniotic 
fluid (Sellers et aL 1982). All uterine tissues, including myornetrium, amnion, chorion and 
decidua are capable of producing PGs from substrate arachidonic acid (Fuchs & Fuchs, 
1996). Therefore, there is no doubt that PG synthesis is involved in human parturition. PG 
actions are mediated by specific receptors (see section 1.4.1) that link to multiple 
mechanisms depending on receptor subtypes (Lye, 1994; Lopez Bernal et al. 1995). Such 
diversity in signalling may explain the conflicting observation of the response to PG in the 
uterus. PGF2,, elevates [C2'] i both by opening C2' channels and by the release of C2' from 
intracellular stores by the activation of phospholipase C (PLC) (Phaneuf et al. 1993), and 
hence stimulates myometrial contraction (Fuchs & Fuchs, 1996). PGE2 activates PLC 
followed by elevating of [C2+]i and activating of MLCK (MacKenzie et al. 1990). 
However, it also increases cAMP production (Lopez Bernal et al. 1991), dependent on EP 
receptor type. 
PGs are formed from arachidonic acid released from cell membranes. Enzymes involved 
in this initial step are PLC and phospholipase A2. Free arachidonic; acid is converted to PG 
through the activity of prostaglandin H synthase, or cyclooxygenase (COX) (Rosen et aL 
1989). Two isoforms of COX have been found. COX-1 is expressed constitutively in most 
types of tissue whereas COX-2 is expressed only following cell activation by cytokines and 
mitogens (see DeWitt, 1991). 
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While synthesis of PGs is regulated initially by activation of phospholipases, PG 
production is also dependent on the level of expression of COX (DeWitt, 1991). COX-1 
and COX-2 have been identified in amnion (Hirst et aL 1995). There is no change in COX- I 
expression whereas the expression of COX-2 has been shown to increase in amnion after the 
onset of labour (Hirst et aL 1995), suggesting that COX-2 is responsible for PG synthesis in 
amnion. The factors that control the expression of COX-2 remain to be identified, but 
interleukin-I (IL-1) has been shown to increase COX-2 mRNA expression in cultured 
amnion cells (Nfitchell et aL 1993a). 
In human myometrium, COX-1 and COX-2 are located in the myometrial smooth 
muscle (Zuo et aL 1994). The expression of COX-2 mRNA and protein in the myometrium. 
increases at term and decreases during labour for both pre-term and term pregnancy. In 
contrast, COX-I expression is lower at term compared to pre-term and not dependent on 
labour (Zuo et aL 1994). From the same study, the amounts of PGE2 and PGF2., have been 
found by immunostaining to be lower in term compared to pre-term and the amounts are 
further decreased with labour. A recent study by Moore et al (1999) has shown that the 
levels of COX- I mRNA expression appears higher at term before labour compared to pre- 
term However, the difference is not significant. For COX-2 mRNA, the levels of expression 
in the myometrium. did not change either with gestational age or with labour. Sparey et al 
(1999) has reported that the levels of expression of both COX-1 and COX-2 proteins are 
not affected by the onset of parturition. In addition, higher levels of expression of these 
enzymes are demonstrated in the lower compared to the upper uterine segment. In contrast 
to these works, Slater et al has reported the up-regulation of COX-2 mRNA and protein in 
the human myometrium. at term but no significant differences are observed in association 
with labour. Taken together, although there is no consistency in the expression of COX-2, it 
indicates an alteration in the cyclooxygenase pathway in the myometriurn during pregnancy. 
Since COX-2 is inducible and short-lived, it is more likely to be restricted to particular areas 
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of activation (KeRy, 1994). Thus, myornetriurn obtained from different areas may provide 
different observations. 
1.5 Regulation of contraction-associated proteins 
It is now believed that myometrial contractility can be controlled by the synthesis of the 
CAPs and uterotonic agents. This concept leads to the physiological questions "what are the 
signals and processes regulating the synthesis and expression of these genes and proteins 
which subsequent influence myometrial function and what is the origin of the signals? ". At 
present, the signals controlling the expression of the CAPs are poorly understood. 
As gap junctions are amongst of the CAPs whose expression increases dramatically just 
prior to the onset of labour, regulation of gap junction expression may reflect the expression 
of other CAPs. Although the regulation of gap junction formation has been studied 
extensively, the mechanisms that regulate the synthesis of gap junctions are still under 
investigation. Based on studies in animals, the expression of Cx-43 mRNA and protein are 
regulated negatively by progesterone and positively by oestrogen (Petrocelli & Lye, 1993; 
Hendrix et aL 1995). Progesterone suppresses Cx-43 gene transcription and inhibits the 
transport of the Cx-43 protein out of the Golgi vesicles (Hendrix et aL 1995). Oestrogen 
can induce increases in Cx-43 mRNA through the synthesis of c-fos and c-jun genes and c- 
Fos and c-Jun proteins in the myornetrium, which would in turn activate an activating 
protein- I (AP-1) binding site in the Cx-43 promoter (Lefebvre et aL 1995; Piersanti & Lye, 
1995). 
In isolated human myometrial cells, oestrogen and progesterone have also been shown 
to affect the levels of Cx-43 expression (Andersen et aL 1993; Zhao et aL 1996). Oestrogen 
causes an increase in the levels of Cx-43 mRNA and protein expression (Andersen et aL 
1993) and progesterone is found to decrease the transcription of Cx-43 mRNA (Andersen et 
aL 1993; Zhao et aL 1996). In contrast to animals, c-Jun and c-Fos, the factors that bind to 
AP-1 sites in the human Cx-43 promoter, are not involved in the mechanism by which 
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oestrogen increases Cx-43 expression in human myornetrial cell culture (Geimonen et aL 
1998). However, c- Fos and c-Jun proteins are found to be increased in the pregnant 
myometrium. that also have elevated Cx-43 expression, suggesting an involvement of these 
proteins in the induction of Cx-43 expression at term in human myometriurn (Geimonen et 
al. 1998). In addition to steroid hormones, protein kinase C (PKQ has been reported to 
induce Cx-43 mRNA expression followed by an increase in Cx-43 protein levels in human 
myornetrial smooth muscle cells through an up-regulation of c-Fos and c-Jun proteins 
(Geirnonen et aL 1996). 
Sex steroid hormones have also been shown to have a role in the regulation of oxytocin 
receptor levels. In animals, oestrogen increases the levels of oxytocin receptors in the 
myometriurn whereas progesterone reduces their levels (Nissenson et aL 1978). In human, 
oestrogen action on the oxytocin receptor probably has the same effect. Progesterone action 
may be different as there is evidence of an increase in the levels of oxytocin receptors in the 
myometrium at term when plasma progesterone levels are high (Fuchs et aL 1984; Kimura 
et aL 1996). An alteration in the oxytocin receptor levels has led Kimura et al (1996) to 
suggest that regulation of oxytocin receptor expression is involved in the process of uterine 
preparation for labour. 
Little is known about the processes involved in the synthesis and expression of other 
CAPs in the human myornetrium. There is evidence to show that transforming growth 
factor-PI (TGFPI) can modify levels of RyR2 expression in a number of cell types 
(Giannini et aL 1992; Neylon et aL 1994). Awad et al (1997) has demonstrated that 
TGFP I induces the expression of RyR2 mRNA in cultured myornetrial smooth muscle cells. 
The authors have suggested that TGFPI may serve as a signal in the myornetriurn and in 
term of RyR2 expression, TGFPI-treated cells are similar to pregnant myornetrium, whose 
RyR2 isoform is up-regulated. 
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The expression of cyclooxygenases in human myometrial cells may also be regulated by 
Interleukin (IL)- 10 (Hertelendy et aL 1999). This results in an increase in PGE2 and PGF2. 
production. Based on these in vitro experiments, it can be hypothesised that cytokines such 
as TGFPI and IL-I are involved in the maturation of the myometriurn in vivo during late 
pregnancy. 
1.6. The contribution of cytokines to human pregnancy and parturition 
There is evidence that intrauterine infection increases production of cytokines by 
gestational tissue, leads to PG synthesis and being followed by pre-term labour Qvfitchell et 
aL 1993b; Mazor et aL 1995). Although there is much evidence supporting the role of 
cytokines in pre-term labour induced by infection, the evidence for their participation in the 
initiation of normal labour is sparse. Fundamentally, term and pre-term labour share a 
common terminal pathway consisting of uterine contractility, cervical dilatation and rupture 
of membranes (Mazor et aL 1995). This has led to the idea that there may be an association 
between cytokines and normal labour. 
Cytokines are a diverse group of polypeptides, secreted in very small amounts by all 
nucleated cell types and involved in a variety of actions. The activities of cytokines are 
mediated via cell surface receptors. Thus, cytokine activity can be regulated either by 
controlling the availability of the cytokines or the expression of receptors. One cytokine 
may have different effects, depending on the target cells. However, most cytokine effects 
involve an altered pattern of gene expression in target cells (Mazor et aL 1995). 
It is increasingly apparent that intrauterine infection is associated with pre-term labour 
and delivery (Romero & Mazor, 1988; Romero et aL 1994). The basis for this concept is 
the fact that bacterial infection in decidua and fetal membranes can stimulate cytokine 
release by the inunune system. Bacterial products as well as cytokines can then induce 
prostaglandin synthesis in human decidua, amnion and chorion (Lamont et aL 1985). 
Cytokines such as interleukin I (IL-1) and turnour necrosis factor alpha (TNFa) can 
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stimulate PG production in many cell types (Mazor et aL 1995). It has been confirmed that 
in human decidua and chorion, these cytokines can enhance the synthesis of PG, which may 
initiate the onset of labour and subsequent delivery the fetus (Norwitz et aL 1992; Pollard et 
aL 1993). In human myometrial. cells, IL- I and TNF stimulate arachidonic acid release, and 
PG production (MoInar et aL 1993). 
Other cytokines whose levels are increased in amniotic fluid of patients with pre-term 
labour in relation to intrauterine infection include IL-6 and IL-10 (Romero et aL 1993; 
Greig et aL 1995). Although much interest has focused on the potential role of cytokines in 
the induction of pre-term labour, they may also be of significant importance in the 
physiological process of parturition. This idea arises from studies by Gunn et al (1996) and 
Stallmach et al (1995) showing that the concentrations of IL-1, IL-6 and IL-8 are high in 
amniotic fluid and maternal plasma with normal pregnancy. It is also found that normal 
spontaneous labour at term is associated with a moderate rise in the levels of TNFa, IL-1 
and IL-6 in amniotic fluid (Saito et aL 1993) and IL-6 in maternal plasma (Arntzen et aL 
1997). IL-1 in amniotic fluid may be secreted from stimulated monocytes or neutrophils in 
decidua, which are recruited to the amniotic space (Cunningham et al. 1993). It has also 
been reported that keratinocytes, which are abundant in amniotic fluid, may be a source of 
amniotic IL-1 (Romero et aL 1989a). TGFP has also been found in amniotic fluid and 
plasma during pregnancy. There is no change in total acid released transforming growth 
factor-P (TGFP)-l levels in plasma during pregnancy (Wakefield et al. 1995) and in 
amniotic fluid in term delivery (Mazor et aL 1995). However, the concentrations of 
TGFP are also increased in human amniotic fluid with pre-term labour and delivery but 
regardless of intrauterine infection (Mazor et aL 1995). Thus, the significance of this 
cytokine remains to be established. 
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1.7 Cytokines and possible roles in normal pregnancy 
1.7.1 IL-1 and IL-1 receptors 
In most systems, two forms of IL- 1, IL- Ia and IL- I P, are synthesised (see Colotta et 
al. 1998). Their biological actions of these two forms are indistinguishable, and the mature 
forms of IL-1 act by way of receptors, type I (IL-IRI) and type II (IL-IRII). IL-1 is 
particularly synthesised in macrophagcs and monocytes. It is also produced in other tissues 
in response to specific stimuli. Stimuli for IL-1 production include toxins from bacteria or 
bacterial products, phorbol esters and other cytokines such as TNFa, interferons and IL-1 
itself The biological actions of IL- I are numerous and are directed at a wide range of target 
cells. Briefly, the role of IL-1 can be defined as the initiation of the defense reaction. IL-1 is 
produced at the site of inflammation. It stimulates surrounding cells such as monocytes and 
lymphocytes to exert its defense actions. Thus, IL-1 initiates a defensive mechanism and 
triggers the immune function (Dinarello, 1991). Consistent with a central role in host 
defence, IL-1 can induce PG synthesis by decidua, amnion and chorion (Romero et aL 
1989b; Pollard et aL 1993), as well as several cytokines including IL-8 and IL-1 itself 
(Dinarello, 1989). Considering the stimulatory effect of IL-1, it is likely that IL-1 forms a 
major step in the gestational inflammatory network (DeJongh et aL 1996). 
Human decidua and placenta are known to be sources of IL-1 (Romero et aL 1989c; 
Taniguchi et aL 199 1; Ammala et aL 1997). IL- IP mRNA expression and protein levels in 
decidua are higher than in placenta (Ammala et al. 1997). Comparing decidual samples from 
non-labouring and spontaneous labouring pregnancies, IL- IP mRNA expression and protein 
levels are higher in labouring samples than in non-labouring samples. IL- IP has been found 
recently in the lower segment of human myornetrium. at term in which the concentration is 
increased during labour and parallel to cervical dilatation (Winkler et aL 1998). In addition, 
there is no increase in the level of IL- IP after 6 cm. of dilation. In the same study, it has been 
found that the level of IL-8 in the myornetrium, changes parallel to the IL- 1P level (Winkler 
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et aL 1998). Thus, it has been hypothesised that IL- IP may be involved in an induction of 
IL-8 in the lower segment of human myometrium. 
IL-1 receptors have been demonstrated in decidua, placenta and fetal membranes 
(Ammala et al. 1997; Whittle et al. 1999). Therefore, IL- I may act in an autocrine fashion 
in decidua and placenta. IL-IRI mRNA expression is stronger in decidua than in placenta 
(Ammala et al. 1997). In decidua, both mRNA and proteins for IL-IRI and IL-IRII are 
expressed. In the fetal membranes, only IL-IRII has been found (Whittle et al. 1999). 
Interestingly, the pattern of receptor expression in decidua does not change with labour 
(Whittle et al. 1999). Specific binding sites for IL-1 have been demonstrated in human 
myornetrial cells in culture (Hertelendy et al. 1993). However, there is no report on the 
expression levels of IL- I receptors in the myornetrium in vivo. 
Importantly, IL-1 is known to act on human amnion, chorion and myometrial cells to 
stimulate PGE2 production (Pollard & NEtchell, 1996; Hertelendy et aL 1993; Pollard et aL 
1993; Romero et aL 1989b). The mechanisms whereby IL-1 stimulates PG synthesis in 
myometrial cells involve stimulation of PLA2 (Hertelendy et aL 1999), which aids a release 
of arachidonic acid from plasma membranes (Molnar et aL 1993), and induction of COX-2 
gene and proteins (Hertelendy et aL 1999). In amnion and chorion cells, the stimulatory 
action of IL-I on PG production involves primarily on the induction of COX-2 (NEtchell et 
aL 1993a, 1993b; Pollard et aL 1993). Collectively, it can be hypothesised that IL-1 may 
serve as a signal for parturition in the humans by acting to stimulate arachidonic acid release 
and induction of COX-2 with a subsequent PG formation in the human uterus. 
1.7.2 IL-8 and IL-8 receptors 
IL-8 is a cytokine that is capable of inducing neutrophil chemotaxis and activation. IL-8 
is produced by a number of cell types including amnion, chorion, decidua, endothelial cells, 
endometrial cells, and fibroblasts (Trautman et aL 1992; Dudley et aL 1993; Arici et aL 
1996; Ueno et aL 1996; Vrmkler et aL 1998). In addition to being a potent chemoattractant 
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for neutrophils, IL-8 appears to have further roles related to reproduction, as evidenced by 
increased levels of IL-8 in anmiotic fluid throughout gestation (Saito et aL 1993). 
IL-8 is present in amniotic fluid during early pregnancy (Srivastava et al. 1996), at pre- 
term and at term delivery, irrespective of intrauterine infection and labour status (Romero et 
aL 1991; Olah et al. 1996). Thus, IL-8 is also a normal constituent of amniotic fluid. 
Amniotic fluid from pre-term labour and delivery contains high levels of IL-8 above that of 
term delivery (Romero et aL 1991). Term parturition is associated with elevated levels of 
IL-8 in amniotic fluid (Romero et aL 1991; Saito et al. 1993). An increase in the level of IL- 
8 during labour has been reported in human amnion, chorion, decidua, placenta and lower 
uterine segment (Osmers et al. 1995; Garcia-Velasco & AricL 1998; Winkler et aL 1998). 
Interestingly, the increased level of IL-8 in the lower uterine segment is significantly 
correlated with cervical dilation (Osmers et aL 1995; Winkler et aL 1998) and increased 
levels of collagenases from invading leukocytes (Osmers; et aL 1995). The levels of 
collagenases (matrix metaloproteinase [MNT-9] and type V collagenase-gelatinase B 
[MNT-9]) increase dramatically with the increasing intensity of labour (Osmers et aL 1995). 
Based on these observations, IL-8 may responsible for the migration of leukocytes and the 
release of these collagenases, which in turn decrease collagen content in the cervix. A 
decrease in cervical collagen content is known to be one of the clinical features of cervical 
ripening, an early event of normal labour (Ekman et aL 1986). Thus, IL-8 may play a 
crucial role in the process of cervical maturation and dilation and may be involved in the 
onset of labour (Osmers et aL 1995). Increased IL-8 levels in amniotic fluid is likely to be 
the result of IL- IP and TNFa stimulation of cells in amniotic fluid. Alternatively, chorion 
and decidua may be another source of amniotic fluid IL-8 (Dudley et aL 1993). In the lower 
uterine segment, IL-8 may be induced by IL-lP and fibroblasts are involved in the 
production of IL-8 in this part of the uterus (Winkler et aL 1998). 
IL-8, unlike IL-1, has no direct effect on chorion, decidua and myometrial cell PGE2 
production (Dudley et aL 1993; el Maradny et aL 1996a; Todd et aL 1996). However, IL-8 
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may act as a secondary signalling mediator to potentiate the inflammatory response, thus 
contributing to PG production (Dudley et aL 1993). The result appears to be the generation 
of uterine contraction. IL-8 can cause a rapid rise in cytosolic free C2' in human 
neutrophils (Tuschil et al. 1992). The relevance of this action of IL-8 in human uterus has 
yet to be determined. Progesterone and TGFP I have been found capable of influencing IL-8 
production in endometrial. cells in culture (Arici et al. 1996a, 1996b). Thus, it can be 
hypothesised that these agents may affect the level of IL-8 in other cell types in intrauterine 
tissues. 
IL-8 exerts its biological activity through two receptors, designated IL-8RA and IL- 
8RB, which are members of the G-protein-coupled receptor family (Holmes et aL 1991). In 
the human uterus, IL-8 receptors have been demonstrated in many tissue types (el Maradny 
et aL 1996b). Using immunohistochemistry, both receptors have been found in fetal 
membranes, placenta, umbilical cord and myometrium samples obtained before the onset of 
labour. In arnnion and placenta, the intensity of staining is greatest in samples collected after 
vaginal delivery compared to those collected before the initiation of labour. This study 
suggests a role for IL-8 receptors during parturition (el Maradny et aL 1996b). There is no 
data available on the regulation of IL-8 receptors in human uterus. In human neutrophils, 
IL-8 itself can modulate the levels of IL-8 receptors (Chuntharapai & Kim, 1995). It can be 
therefore postulated that IL-8 may influence the level of IL-8 receptor expression in human 
myometrium. 
1.7.3 TGFP and TGFP receptors 
TGFP belongs to a family of multifimctional cytokines that are involved in the 
regulation of cell growth, development and differentiation, and extracellular matrix 
formation (Massague, 1990; Massague et aL 1994). There are three different isoforms of 
TGFP denoted TGFP I, TGF02, and TGFP3 (Massague, 1990). TGFP is first synthesised in 
cells or tissues as a large precursor molecule with an amino-terminal signal sequence, 
mature C-terminal peptide, and additional protein called latent TGFP binding protein (Brand 
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& Schneider, 1995). This secreted TGFP is an inactive latent complex that will not bind to 
cell membrane receptors. Activation of this complex by proteolysis, acid or heat releases a 
mature 25-kDa protein, which consists of two identical disulphide-linked monomers 
(Barnard et aL 1990). This process is probably an important physiological regulator for 
TGFP activity (Kingsley, 1994). Three types of receptors with the molecular mass of 50-80, 
85-110 and 200-400 kDa have been named as TGFP receptor type 1,11 and III (TPRI, 
TORII and TPRIII). These receptors appear to be expressed in most mammalian cells 
(Massague, 1990; Kolodziejczyk & Hall, 1996). 
It has been suggested that the immunosuppressive activity of amniotic fluid may be 
important in regulating maternal immunity during pregnancy (Shohat & Faktor, 1988). This 
activity of amniotic fluid has been found to correlate with the presence of amniotic fluid 
TGFP (Lang & Searle, 1994). A role for TGFPl in regulating the maternal immune 
response, preventing rejection of the fetus and regulating human implantation has been 
proposed (Kauma et aL 1990; Srivastava et al. 1996). This is because the presence of 
TGFPI in human decidua, placenta, placental membranes and amniotic fluid at first 
trimester (Kauma et aL 1990; Srivastava et aL 1996). In addition to TGFP, its receptors 
have also been demonstrated in human placenta (NEtchell et aL 1991; Mtchell & O'Connor- 
McCourt, 1992). It has been shown that the level of TGFP is increased in human amniotic 
fluid with pre-term labour, regardless of intrauterine infection (Mazor et aL 1995). Thus, it 
is reasonable to suggest that TGFP is a physiological cytokine, which may possesses 
different roles at different stages of pregnancy. 
In human, although TGFP and TGFP receptors have been studied at length in non- 
pregnant myometrium, little is known about TGFP in pregnant myometrium. Therefore, the 
following information is from observations at different reproductive stages in human non- 
pregnant myometrium. Human myometrium. expresses both mRNA and proteins of all 
TGFP isoforms as well as TPRI-III, which are localised in non-pregnant myometrial smooth 
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muscle (Chegini et aL 1994; Dou et aL 1996). This finding suggests an autocrine role of 
TGFP in the smooth muscle of the myometrium. It has been reported that the expression of 
TGFP mRNA in the myometrium does not change throughout the menstrual cycle. In 
contrast, the levels of TGFP mRNA in human endometrium are higher during the secretory 
phase than the proliferative phase of the menstrual cycle, thus indicating regulation by 
ovarian steroids, in particular progesterone in the endometrium (Chegini et aL 1994; Bruner 
et aL 1995; Casslen et aL 1998). The role for TGFP in human myometrium is still unknown. 
Because of the presence of TGFP and its receptors in the myometrium and its role in cell 
growth and differentiation, it is possible to hypothesise that during pregnancy, TGFP 
influences myometrial differentiation and promote the growth of the myometrium. 
Myometrial smooth muscle cells in culture contain both TGFP 1-3 and TPRI-III mRNA 
and proteins, and they can synthesise and release TGFPI into culture media (Tang et aL 
1997). It has been found that TGFP I can stimulate DNA synthesis but has no effect on cell 
proliferation in cultured myometrial smooth muscle cells (Tang et aL 1997). Based on this 
study, TGFPI has been suggested to play a role in cellular hypertrophy in myornetrial. 
smooth muscle cells. This role of TGFP I may occur in myometrial smooth muscle in vivo, 
causing uterine enlargement during pregnancy. TGFP1 can act on human myometrial. 
smooth muscle cells to increase mRNA levels of parathyroid hormone-related protein 
(PTH-rP), immunoreactive PTH-rP secretion (Casey et aL 1992) and RyR2 mRNA 
expression (Awad et aL 1997). Although PTH-rP is one of several agents involved in 
myornetrial quiescence (Morimoto et aL 1997), a role for PTH-rP in the initiation of 
parturition has been suggested (Paspaliaris et aL 1995). Thus, taken together, TGFP I may 
be one of the signalling agents that operates in the human myornetriurn during late 
pregnancy to regulate cell growth, promote synthesis of functional proteins and prepare the 
myornetrium. for labour (el Maradny et aL 1996a; Awad et aL 1997). TGFPI has been 
shown to have a role in the synthesis of other proteins such as endothelin-I as seen in 
decidua and amnion cells during pregnancy (Kubota et aL 1997; McKenna et aL 1998). 
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It has been suggested that TGFP 1 acts as a gene-specific antiprogestin (for reviews see 
(Casey & MacDonald, 1996,1997). This view is based on the findings that TGFP 
attenuates the effect of progesterone on some genes such as endothelin and PTH-rP in 
endometrial. stromal cells, and gap junction protein, Cx-43, in the myometrium. Possibly, the 
inhibition of the progesterone response' by TGFPI can be thought as an alternative 
mechanism to progesterone withdrawal in human, thus contributing to the initiation of 
parturition. 
1.8 Regulation of the levels of TGF, 8 mRNA, TGFfl secretion and activation 
1.8.1 Role of sex steroid hormones 
Steroid hormones can be divided into three classes; the adrenal steroids, sex steroids 
and vitamin D3- It is well known that sex steroid hormones are crucial and elicit complex 
biological responses in the reproductive system (Koli & Keski-Oja, 1996). Cytokines are 
now accepted to be involved in uterine functions. An understanding of the role for cytokines 
in reproductive physiology, especially, during pregnancy is still in its infancy. TGFP which 
participates in reproductive functions as observed in animals and in humans (Tamada et aL 
1990; Das et aL 1992; Chegini et al. 1994) has been described as a universal biological 
switch which is responsible for transmitting signals to the cells (Roberts & Sporn, 1993). It 
has been observed that steroid hormones can affect the levels of TGFP mRNA and proteins 
in a cell and tissue specific manner (Wakefield et aL 1990). Thus, in this section only the 
role of sex steroids on the expression and secretion of TGFP in human uterus is reviewed. 
Sex steroids are known to influence the levels of TGFP mRNA and the amount of 
latent TGFP secretion. In endometrial. stronmI cells, oestradiol causes a slight increase in 
the level of TGFP I niRNA and a greater increase in TGFP3 mRNA. Medroxy progesterone 
acetate (M[PA) affects a very small increase in TGFPI mRNA level but causes a marked 
decrease in the level of TGFP3 niRNA (Arici et aL 1996). A slight increase in TGFP I and 
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an inhibition of TGFP2 secretion have also been demonstrated in endometrial stromal cells 
after oestradiol and progesterone treatment, respectively (Kanzaki et aL 1995). Addition of 
progesterone to endometrial explants enhances production of TGFP2 mRNA (Bruner et aL 
1995) and a combination of oestradiol and progesterone increases the level of TGFP1 
mRNA (Casslen et aL 1998). These findings indicate a network between endocrine and 
cytokine systems in human endometrial cells. 
In human myornetrial cell cultures, oestradiol, and in particular NTA and WA plus 
oestradiol stimulate the production of total TGFP I (latent plus active) (Chegini et aL 1996). 
According to this study, the proportion of active TGFP1 released into culture media is 
reduced by these steroids. This demonstrates an interaction between endocrines and 
cytokines in myometrial cells and presumably in the myornetrium. Generally, TGFP is 
secreted from cultured cells as a latent complex, which remains biologically inactive until 
the latent complex is broken down. The mechanism involved in the release from latency is 
uncertain in vivo but in vitro, proteolytic cleavage by proteases such as plasmin may be 
involved (Lyons et aL 1990). Thus, activation of latent TGFP may be regulated by sex 
steroids in myometrial smooth muscle cells. This mechanism may potentially regulate 
TGFP I activity in the cells. The effect of sex steroids on other isoforms of TGFP in human 
myornetrial cells has not yet been studied. 
The mechanisms whereby sex steroid hormones affect the levels of TGFP genes and the 
amounts of secreted TGFP are not clearly understood. Most steroid-inducible genes contain 
at least one response element in the regulatory region of the gene. It has been reported that 
the human TGFP3 gene contains an oestrogen response element (Yang et aL 1996), but 
there is no oestrogen response element in the TGFPl promoter (Kim et aL 1989). It has 
been reported that the human TGFPI promoter region contains activator protein-1 (AP-1) 
sites (Kim et aL 1990; Scotto et aL 1990) and oestrogen is known to up-regulate the 
expression of c-fos and c-jun genes, which are components of AP-1 (Loose-Mitchell et aL 
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1988; Weisz et aL 1990). Thus, stimulation of TGFP I by oestrogen may be regulated by the 
activation of transcription factors. 
In other human cell types such as breast cancer cells, growth inhibition by some 
synthetic progestin does not involve progesterone receptor, but appears to be mediated via 
intracellular binding site (Colletta et aL 1991). Progestin can also increase the level of 
secreted TGFP1 without affecting TGFP1 mRNA (Colletta et aL 1991). Thus, sex steroid 
hormones may affect the induction of TGFP at post-transcriptional levels including 
efficiency of translation, post-translational processing or stability of TGFP1 protein. The 
post-transcriptional mechanisms have been suggested for TGFP induction in cells that lack 
oestrogen receptors such as human fetal fibroblasts (Colletta et aL 1990). 
1.8.2 Role of cAMP 
There is evidence to suggest that cANT has a strong effect on the induction of TGFP 
gene expression in normal trophoblasts, choriocarcinoma cells and pituitary cells (Ritvos & 
Eramaa, 1991; Pastorcic & Sarkar, 1997). As both cAMP and cytokines participate in the 
complex physiology of human gestation, it is reasonable to assume that these systems may 
interact with each other and play a role in co-ordinating the events of maintenance or 
termination of pregnancy. Unfortunately, the effects of cANV on TGFP gene expression 
and TGFP secretion in the human uterus has not been well documented, except in 
trophoblast cells. 
In normal and malignant trophoblast cells, TGFP1 mRNA levels have been induced by 
the cAND analogue, 8-bromo-cANT, during a 48-h stimulation (Ritvos & Eramaa, 1991). 
It has been found that 8-bromo-cAND has a slow effect on the activation of TGFP I mRNA 
expression, implying an indirect regulation by this agent. cANV has been shown to induce c- 
fos and c-jun, which act as transcription regulators through AP- I binding sites (Bravo et al. 
1987; Nakamura et aL 1990). The TGFPI promoter contains no element resembling the 
cAMP-responsive element (CRE) sequence but contains activator protein-1 (AP-1) sites 
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(Kim et aL 1990; Scotto et aL 1990). Thus, cANT may affect the expression of TGFPI 
mRNA through AP- I binding sites present in the TGFP I promoter (Geiser et aL 1991). A 
direct stimulatory effect of cANV through the AP-2 transcription factor on the TGFPI 
gene, which mediate cANT responses can not be excluded (Ritvos & Eramaa, 1991; 
Pastorcic & Sarkar, 1997). Alternatively, the effect of cAW may result from post- 
transcriptional control of TGFP 1 mRNA (Ritvos & Eramaa, 199 1). 
1.8.3 Role of cytokines 
Cytokines are able to induce or inhibit synthesis and secretion of other cytokines. Thus, 
it has been extremely difficult to define which cytokine is responsible for a given 
physiological effect. A given effect may be caused by the secondarily induced cytokine 
rather than the primary and sometimes the full response depends on synergy between the 
cytokines (Clemens, 1991). It is known that cytokines have variety effects in human 
pregnancy and labour. TGFP 1, in particular, has been hypothesised to promote the synthesis 
of functional proteins in human myometrium. during late pregnancy (el Maradny et aL 
1996a; Awad et aL 1997). Relatively little is known about how TGFP1 is produced in the 
myometrium. TGFPI production in myometrial smooth muscle cells may be caused by 
TGFP I itself (Tang et aL 1996) or by other cytokines present in the uterus such as IL- I as 
reported in other cell types (Colasante et aL 1997). The induction of TGFPl expression 
may be regulated at several levels. These include transcription of the TGFP I gene through 
AP-1 binding sites, stability of mRNA and the efficiency of mRNA translation as described 
earlier. 
Under natural conditions, cells have been exposed to several cytokines and other active 
agents at the same time, resulting in various interactions and numerous biological effects. As 
can be seen in section 1.8.1-1.8.3, several agents can regulate TGFPI expression and 
production. This suggests interactions between different systems for the effective operation 
of TGFP I in the cells. 
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1.9 Choke of cytokines 
From the review above, three cytokines, TGFPI, IL-1 and IL-8, and their receptors 
were chosen for study in this thesis. All TGFP isoforms have been found in the human 
myometrium and myornetrial cells in vitro, with TGFP3 being the least expressed (Chegini 
et aL 1994; Tang et al. 1997). It is known that myometrial smooth muscle expresses high 
levels of TPRII and an interaction between TPRI and TPRII is necessary for mediating the 
biological activities of TGFP. However, the type I receptor is used for signalling. 
Moreover, the intracellular C2' release channel, RyR2, has been found to be up-regulated 
in human myometrial cells following TGFPI treatment (Awad et al. 1997). Thus, TGFP1 
and TPRI regulation are the principle cytokine elements investigated in this thesis. 
The second cytokine studied is IL-1, along with IL- I receptor type 1. IL- I is the major 
cytokine found in the amniotic fluid of pregnant women with intra-uterine infection (Mazor 
et al. 1995). IL-I is also known to be involved in the mechanism of pre-term labour. This 
cytokine-induced activity is mediated exclusively via IL-IRI (Colotta et al. 1998). For these 
reasons, IL-I and its receptor type I were chosen. 
IL-8 is another cytokine chosen for investigation. This cytokine has been recognised as 
having a role in cervical ripening and maturation. IL-8 is present in amniotic fluid 
throughout pregnancy (Romero et al. 1991; Olah et al. 1996; Srivastava et al. 1996) and 
the intra-uterine levels increase during labour (Osmers et al. 1995; Garcia-Velasco & AricL 
1998; Winkler et al. 1998). There are two types of receptor mediating the IL-8 response. In 
the present study, IL-8 receptor type B was selected as this receptor has been reported in 
the myornetrium. and suggested for a role in human parturition. However, there is no data 
available on the alteration of the receptor expression in the myornetrium. during pregnancy 
and the regulation of the receptor. It is therefore of interest to examine the possible role of 
this cytokine in myornetrial smooth muscle. 
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AIMS OF THE STUDY 
The physiological mechanisms that initiate the onset of labour have been studied 
extensively in animals. It is believed that an essential part of this process involves the 
regulation of expression of genes encoding a cassette of proteins associated with 
contraction in the myometrium, the contraction associated proteins (CAPs). An alteration in 
the expression of CAPs has also been shown to occur in the human myornetrium as term 
approaches and before the onset of labour. Given this perspective, the onset of labour 
begins when these proteins are in place. Thus, an understanding of the regulation of the 
expression of these proteins would be of great benefit to the management of labour. This 
was the overall objective of this study. 
Previous work from this laboratory has suggested that the intracellular Caý' release 
channel RyR2 is a CAP present in the human myometrium at term. Furthermore, the 
cytokine TGFP 1 may be involved in the regulation of RyR2 in cultured myometrial cells. If 
this idea is correct, then it raises the hypotheses 
1. 'that TGFfll and TGFfl receptors are present in the myometrium at term. 
2. 'that expression changes with gestation. 
The specific aim of this thesis was to examine these hypotheses. If TGFPI and TGFP 
receptor expression change in term pregnant myornetrium, this raises a further question 
regarding the mechanisms regulating expression. Thus, the second general aim of this thesis 
was to use myornetrial cells in vitro to examine the effects of cytokines such as TGFP I, IL- 
I and IL-8, sex steroid hormones and cAW on the expression of TGFPI and TGFP 
receptor type 1. 
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Chapter 2 
METHODS 
ZI Myomettial collection and ethical approval 
2.1.1 Myometrial collection 
Samples of myometrium. were taken from the uterine segment from pre-menopausal 
patients undergoing hysterectomy or caesarean section at Royal Victoria Infirmary, 
Newcastle upon Tyne. Control samples from non-pregnant women of reproductive ages 
(n =3 0) were obtained from patients undergoing hysterectomy due to benign 
gynaecological disorders such as benign tumours. In this group, myometrial samples were 
taken from the anterior wall of the lower uterine body, immediately following hysterectomy. 
In the case of caesarean section, myometrial samples were obtained from the upper margin 
of the lower uterine segment. Samples of pregnant myometrium. were collected from three 
groups of women as follows: 
1. Pre-term women (31-35 weeks gestation, n= 5) without intrauterine infections and labour 
pain: myometrial samples were obtained at caesarean section due to fetal distress or small 
for gestational ages. This group was called the pre-term non-labouring group. 
2. Term pregnant women (38-40 weeks gestation, n= 22) who had not entered labour: 
myornetrium. was obtained from patients with no complications at elective caesarean section. 
The indications for caesarean section were either previous section or cephalo-pelvic 
disproportion. This group was called the term pregnant non-labouring group. 
3. Term pregnant women (38-40 weeks gestation, n= 20) who were in regular uterine 
contractions with the cervix 6-10 cm dilated. The diagnosis for this group was fetal distress 
or faure to progress. In this group, amniotic membranes were intact with no history or 
presence of infection at the time of caesarean section. Patients who had augmentation of 
labour with oxytocin were included in this group. This group was called the spontaneous 
labouring group. 
I 
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2.1.2 Ethical approval 
Patients were consented for myometrial biopsies on the day before their operations in 
the case of hysterectomies and planned elective caesarean sections or immediately prior to 
the operations in the case of emergency caesarean sections. The present study had ethical 
approval from the Newcastle Area Health Authority. 
2.1.3 Removal of myometrium from the uterus 
Samples of Ixlx2 cm were removed from the lower anterior uterine segment and 
placed in collection medium (Medium 199 supplemented with 2 mM glutamine, 500 units 
penicillin and 100 pg/ml streptomycin). The myornetrium. was excised about 5 mm away 
from the decidua, serosal layer, or turnour. Since it has been reported that these tissues may 
contain cytokines or cytokine receptors, it was important to remove all such tissues from 
the myometrium. Great care was taken to obtain pure myometrial samples. Samples were 
washed in phosphate-buffered saline (PBS) and cut into small pieces before being rapidly 
frozen in liquid nitrogen. Samples were kept at -70 'C until used for preparing myometrial 
lysates (see section 2.2). Samples of myometrium. were also used for immunohistochernistry 
using a paraffin-embedding technique (see section 2.3). In this case, the samples were kept 
in formaldehyde. In addition, non-pregnant myometriurn samples were used to prepare 
cultured cells. These samples were diced into small pieces and myometrial cells were 
isolated using enzymatic digestions (see section 2.4.1). 
Z2 Preparation of human myometrial lysate 
Small pieces of individual frozen myornetriurn from each group were weighed and then 
thawed in 3 volumes of cold homogenising buffer containing 25 mM Tris base, pH 7.6, 
0.25 M sucrose and I mM EDTA (Europe Finner et aL 1993). The myometrium was 
further disrupted by mechanical hornogenisation on ice. The hornogenates were then 
centrifuged at 1,500 g for 30 min at 4 *C. The supernatants were removed and re- 
centrifuged to obtain clear lysates. Protease inhibitors: 5 gghnI of pepstatin A, 5 pghnl 
31 
Methods 
leupeptin and 5 pghnl aprotinin were added into the lysates to prevent protein degradation. 
The protein content in lysates was measured by the method of Bradford (1976) (see section 
2.6). Myornetrial lysates were aliquoted and kept frozen at -70 *C until used. 
2.3 Immunohistochemistry 
2.3.1 Tissue section determination of TGFP receptors in human myometrial smooth 
muscle 
Non-pregnant, term pregnant non-labouring and terrn spontaneous labouring 
myometriurn were washed with C2+/Mg2+ free PBS and the serosal layer removed. Samples 
of myometrium. were fixed in 4% formaldehyde buffered to prevent structural changes in 
the tissues. The fixed tissues were dehydrated by placing in absolute alcohol. This step was 
essential because in this technique all the water in tissues is replaced by paraffin wax so that 
the tissue blocks can be sliced easily. Once absolute alcohol had replaced water in the 
tissues, the tissue blocks were passed through xylene three times, with the result that xylene 
replaced the alcohol in the tissues. Warm paraffin wax, which is soluble in xylene was 
introduced to the tissue blocks until the tissues become saturated with paraffin. Tissue 
sections (5 jim) were then cut with a microtome, placed onto glass slides for use. 
2.3.2 Indirect immunostaining method 
Before sections were stained, paraffin was removed by xylene. The slides were then 
hydrated through the decreasing concentrations of alcohol (100 %, 95 % and 50 %) and 
finally tap water for 2 min each stage to remove Xylene. The endogenous; peroxidase activity 
was blocked by incubating the slides with 3% hydrogen peroxide for 10 min and 
subsequently washing for 2 min with tap water and PBS, pH 7.3. The slides were incubated 
for 30 min with blocking serum derived from the same species in which the secondary 
antibody was made. In this experiment, the blocking serum was goat serum. Excess serum 
was removed and the slides were now ready for staining with primary antibodies. 
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The slides were incubated with rabbit antibodies to TGFP receptor types 1,11 and III 
from Insight Biotechnology at a concentration of 3 pg/ml diluted in PBS with I% goat 
serum for 2-3 h in a humidified chamber. The slides were washed three times for 5 min each 
time with PBS and incubated with horseradish peroxidase (HRP)-conjugated goat anti- 
rabbit IgG (1: 100) from Dako for 45 min. The slides were washed twice with PBS and the 
bound antibodies visualised by incubating the slides with freshly prepared diaminobenzidine 
(DAB) for 5 min or until a brown stain was seen. The slides were washed for 2 min with tap 
water, counter-stained with hernatoxylin for I min and rinsed immediately with running tap 
water. The stained slides were dehydrated through 95 % alcohol, absolute alcohol, and then 
through xylene for I min each stage. The excess xylene was wiped off and I or 2 drops of 
xylene-based mounting medium added, covered with glass coverslips, observed under light 
microscope and photographed. A negative control was processed in an identical manner, but 
in the absence of primary antibody. All procedures were carried out at room temperature. 
Z4 Human myometrial cell culture techniques 
I 
2.4.1 Isolation of human myometrial smooth muscle cells 
Myometrial smooth muscle cells were prepared by enzymatic digestion using a 
technique modified from the procedures described by Morgan et al (1993). Samples of non- 
pregnant myornetrium. in sterile collection medium were dissected from any adherent 
endometrium and washed twice with Caý+/Mg2+ free PBS. The cleaned myornetrial tissue 
samples were sliced into small pieces and placed in sterile tubes. 5 n-A of digestion enzymes 
composed of 5 mg collagenase, 0.1 mg DNase, I mg trypsin inhibitor, 1 mg elastase and 
I mg bovine serum albumin fraction V in C2+/Mg2+ free PBS were added into each tube. 
The myornetrial slices were digested at 37 T with shaking for 2 IL Enzyme solutions 
containing cells were removed to sterile centrifuge tubes and the connective tissues were left 
behind. 5 n-A complete medium [collection medium supplemented with 10 % fetal calf serum 
(FCS)] was added to the tubes to stop enzyme action and to prevent cell damage. The tubes 
were centrifuged for 10 min at 400 g and cell pellets re-suspended in 10 n-A complete 
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medium. The cell suspensions were transferred to sterile 75 crný flasks and placed in a5% 
C02 humidifying incubator at 37 T. The cells were left in the flasks for approximately 24 h 
to allow cells to attach. Once cells were attached the medium was changed and the new 
complete medium was replaced twice a week. Normally, confluence was achieved within 10 
days in culture. This may depend on the yield of cells obtained from digestion and cells 
plating density. 
2.4.2 Cell passage 
Confluent cells were washed twice with 15 n-A C2+/Mg2+ free PBS to remove any FCS 
and C2', which would interfere with the action of the enzyme trypsin. Cells in 75 cný flasks 
were incubated at 37 *C with 5 ml of 0.5 g/L trypsin containing 0.2 g/L EDTA for 10 min. 
The flasks were gently shaken to detach cells from the base of the flasks. If cells were seen 
rounded up and phase bright in the enzyme solution, 5 n-A of complete medium was added to 
terminate enzyme action. The cell suspensions were transferred to centrifuge tubes, 
centrifuged for 10 min at 400 g and cell pellets re-suspended in 10 mI complete medium. 
The cells in complete medium were passed gently through a pipette approximately 5 times 
to dissociate the clumps of cells. After cell number estimation (see section 2.4.3), 1X 106 
cells were diluted in 15 ml culture medium and plated into 75 cn? flasks for further culture. 
Cells required for experiments were seeded either onto 12 well tissue culture plates (5 x 10' 
cells/well) or 25 crný flasks (2 x 10' cells). Cell counts were made each day for the period of 
10 days. Seeding at these numbers of cells would allow approximately 7 days for the cells to 
achieve confluence. Confluent cells from passage one to passage six were used in all 
experiments. 
2.4.3 Estimation of cell numbers 
The concentration of ceRs was deterniined, where necessary, by counting the ceRs in a 
haemocytometer (Improved Neubauer). CeUs were trypsinised and 20 gl of ceU suspension 
was counted in duplicate. For routine subcultures, 100-300 cells per mrrý were counted and 
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for experiments, 500 cells per mný were counted. The two counts were aVeraged and the 
concentration of cells were calculated from the following formula 
c= n/v 
Where c= cell concentration (cellslml), n= number of cells count, and v= volume counted 
(ml). For the Improved Neubauer slide, the central I mný was used and the depth of the 
chamber is 0.1 mm, thus, v=0.1 mn? or Ie ml. The formula becomes 
c= nx 104 
2.4.4 Verification of myometrial smooth muscle cell purity 
In order to ensure that cells were myometrial smooth muscle, cells were verified by 
immunoperoxidase staining with monoclonal antibodies to smooth muscle cc-actin and 
calponin from Dako. Confluent cells grown on sterile glass coverslips were washed twice 
with PBS. The cells were then fixed with 95 % methanol for 10 min. After fixing, the 
coverslips were rinsed briefly with PBS. The cells were permeabilised with 0.05 % saponin 
in de-ionised water for 15 min and washed twice with PBS. The cells were then incubated 
for 10 min in 3% hydrogen peroxide to quench endogenous peroxidasc activity. 
Subsequently the cells were washed in running tap water and PBS for 2 min each. The cells 
were incubated in blocking serum derived from the same species in which the secondary 
antibody was made for 30 min to suppress non-specific binding of IgG. Excess blocking 
serum was removed before incubation with primary antibodies. The subsequent incubations 
were carried out in a humidified chamber at room temperature. The coverslips were covered 
with 100 pI of mouse anti-smooth muscle oc-actin and calponin antibodies at 1: 20 and 1: 40 
dilutions, respectively and incubated for 90 min at room temperature. The coverslips were 
washed with three changes of PBS. After the washing steps, cells were incubated for 45 min 
with BRP-conjugated goat anti-mouse-IgG (1: 100). The cells were then washed twice for 5 
min each time with PBS, incubated in freshly prepared diaminobenzidine (DAB) solution for 
5 min or until brown staining was visible and subsequently washed for 2 min with tap water. 
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The cells were counter-stained with hematoxylin, rinsed in running water and mounted in 
aqueous mounting medium. Negative control myometrial cultured cells were processed in 
an identical manner, but the primary antibody was replaced with mouse IgG. Specificity of 
these two antibodies to smooth muscle was checked by incubation of fibroblast cells derived 
from human prostate with these antibodies in the same manner. The immunostaining was 
observed by light microscopy and photographed using a Nikon FG-20 SLR camera loaded 
with Fujichrome tungsten balanced film, attached to the front port of the microscope. 
Results show that only a few fibroblast cells are positively stained with these antibodies. 
Additionally, greater than 95 % of myometrial cells are positively stained, suggesting that 
they are of smooth muscle origin. Figure 2.1 shows photomicrographs of confluent 
myornetrial cells and fibroblast cells stained with cc-actin and calponin antibodies. 
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Figure 2.1 Immunoperoxidase staining for (x-actin and calponin in monolayer cultures of 
myometrial smooth muscle cells and fibroblast cells. 
The figure shows photornicrographs of culture myometrial smooth muscle cells. column A and 
fibroblast cells, column B. Both cell types were stained with mouse IgG (a), (x-actin (b) and 
calponin (c). 
Methods 
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2.5 Treatment of cultured myometilal smooth muscle cells with Cytokines, 
steroid honnones, antibodies to cytokines and forskolin 
In these investigations, myometrial. cells were treated with IL-1 at a dose chosen to be 
maximal for prostaglandin stimulation in human myometrial cells (10 ng/ml) (el Maradny et 
al. 1996a; Todd et al. 1996). This concentration has also been reported to exist in the 
amniotic fluid of women with infection-associated pre-term labour (Romero et al. 1989a). 
The dose of IL-8 (150 ng/ml) was chosen from a range that stimulates transient mobilisation 
of C2+ in human keratinocytes (Tuschil et al. 1992). For the stimulation of cells with 
TGFPI, I ng/n-A was used as the RyR2 mRNA in the human myometrial cells can be up- 
regulated at this concentration (Awad et al, 1997). 
In this study the myometrial cells in vitro were maintained in the medium containing 
serum. All of the experiments were done from this base line condition. It is well known that 
serum can contain many factors, which may affect the responsiveness of cells. However, in 
this thesis we chose to work under conditions where the cells were viable and healthy (i. e. in 
serum containing medium). It must be borne in mind that the data obtain are therefore 
specific for serum-treated cells. 
2.5.1 IL-1 and IL-8 treatment and determination of TGF01 and TORI expression 
Myometrial cells were cultured in 12 well Plates until confluence. The cells in complete 
medium were incubated for 24 h with or without IL-1 (10 nghnI) or IL-8 (150 ng/ml). The 
bathing culture medium was collected at the end of each treatment and centrifuged at 
1000 g for 10 min at 4 T. Supernatants were kept at -70 T for subsequent determination 
of TGFP I levels using enzyme-linked immunosorbent assay (ELISA) as described in section 
2.10. The cells were washed with C2+/Mg2+ free PBS and trypsinised. The trypsinised cells 
in complete culture medium were centrifuged at 400 g for 5 min. The cell pellets were 
washed, re-suspended in 40 [d homogenising buffer containing protease inhibitors (see 
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section 2.2) and passed through a pipette five times. The protein content was determined for 
each sample by the Bradford assay (1976). The level of TPRI in cells was determined using 
electrophoresis and immunoblotting (see section 2.7-2.8). 
2.5.2 TGFPI and IL-8 treatment and determination of TPRI and IL-8RB 
Confluent myometrial cells in 12 well plates were treated for 24 h with or without 
TGFPI (1 ng/ml) and IL-8 (150 nghnl) in complete culture medium. After treatments, the 
cells were processed as described in section 2.5.1 and the levels of TPRI and IL-8RB 
determined using Western immunoblotting analysis (see section 2.7-2.8). 
2.5.3 Sex steroid hormones treatment and determination of TGFPI and TPRI 
Confluent myometrial cells in 12 well plates were treated for 24 h with 170-estradiol 
(10 and 100 nM), progesterone (100 and 200 nM) or in combination with IL- I (10 ng/n-A) 
or IL-8 (150 ng/n-d). Control cells received complete medium alone. At the end of each 
treatment the bathing culture medium was collected and centrifuged at 1000 g for 10 min at 
4 T. Supernatants were kept at -70 T for subsequent determination of TGFP I levels using 
ELISA as described in section 2.10. The cells were processed as described in section 2.5.1 
and the levels of TPRI in cells determined using Western immunoblotting analysis (see 
section 2.7-2.8). 
2.5.4 Cytokines and cytokines neutralising antibodies treatment and determination of 
TPRI 
Confluent myometrial cells in 25 cmý flasks were pre-incubated for 3h with TGFPI 
neutralising antibody (TGFPI(NA)) or IL-I neutralising antibody (IL-I(NA)) from R&D 
systems at concentrations of 3 ýtghnl or 0.5 pghnL respectively. Following pre-treatment 
with TGFPI(NA), the cells in complete culture medium were incubated for 24 h with IL-I 
(I nghnl) or IL-8 (150 nghnl) in the presence of neutralising antibody. For the cells pre- 
treated with IL-I(NA), the cells were stimulated with IL-8 (150 ng/ml) for 24 h. Cells were 
also treated with IL-I and IL-8 in parallel to these treatments. Control cells were incubated 
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in complete culture medium alone. The cells were harvested and the levels of TPRI 
expression determined using Western immunoblotting analysis (see section 2.7-2.8). 
2.5.5 Cytokines and cytokines neutralising antibodies treatment and determination of 
cyclooxygenase-2 (COX-2) 
Confluent myometrial cells in 25 cmý flasks were pre-incubated for 3h with TGFPI 
neutralising antibody (TGFPI(NA)) or IL-I neutralising antibody (IL-I(NA)) at concentrations 
of 3 pg/ml or 0.5 pg/n-A, respectively. Following pre-treatment with TGFPI(NA), the cells in 
complete culture medium were incubated for 24 h with IL- I (I ng/nil) in the presence of 
neutralising antibody. For the cells pre-treated with IL-I(NA),, the cells were stimulated for 
24 h with TGFP I (I ng/n-d). The cells were also treated with TGFP I and IL- I in parallel to 
these treatments. Control cells were incubated in serum culture medium alone. The level of 
COX-2 expression was determined at the end of treatment using Western immunoblotting 
analysis (see section 2.7-2.8). 
2.5.6 Forskolin treatment and determination of TGFP1, TPRI, c-Fos and c-Jun 
Confluent myornetrial cells in 12 well plates were incubated for 24 h, 48 h and 72 h 
with forskolin (5 pM) in the presence of serum. The control cells were incubated in 
complete culture medium alone. At the end of treatment, culture medium was removed and 
centrifuged at 1000 g for 10 min at 4 OC. The levels of TGFP I in cultured supernatants were 
measured using TGFPl ELISA (see section 2.10). The cells were washed with PBS and 
lysed with lysis buffer supplied in cAMP assay kit (see Appendix 5). Intracellular cANT 
levels were measuredusing a cANT enzyme immunoassay (see section 2.11). In addition, 
confluent cells in 25 ctný flasks were incubated for 45 min, 2 h, 24 h, 48 h and 72 h with 
similar treatment. At the end of each incubation period, the cells were harvested and 
processed as described in section 2.5.1. Levels of TPRI, c-Fos and c-Jun were analysed 
using Western immunoblotting (see section 2.7-2.8). 
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2.5.7 TGFPI treatment and determination of the G protein sub-units (Ga. and Gaij, 2) 
Confluent myornetrial cells in 12 well plates were treated for 24 h with TGFP I 
(I ng/ml). After treatments, the cells were processed as described in section 2.5.1 and the 
levels of Ga. and Gail, 2 in the cells determined using Western immunoblotting (see section 
2.7-2.8). 
Z6 Total protein assay 
Protein concentration was assayed using a Bio-Rad Protein assay kit based on the 
method of Bradford (1976). This method is based on the observation that Comassie Brilliant 
Blue G-250 exists in two different colours, red and blue. When binding to protein occurs, 
the maximum absorption of the dye shifts from 465 to 595 run as the red form is converted 
to the blue form. The differential colour change of the dye because of various amounts of 
protein is determined at 595 nnL 
To assay protein concentration, several dilutions of bovine albumin (200-1400 gghnl) 
were prepared. A standard curve was carried out each time the assay was performed. 
Samples, to be assayed, were diluted in distilled water. The concentrated dye reagent was 
diluted 1: 4 with distilled water. 
Protein standards and appropriately diluted samples in a volume of 20 111 were added 
into dry test tubes. 20 gl of distilled water was also placed in a test tube as a blank. Diluted 
dye reagent (I ml) was added to each tube and the contents mixed gently. After incubation 
between 5-60 min at room temperature, the absorbance at 595 nm was measured against a 
reagent blank. A standard curve was plotted and protein concentrations in the samples 
calculated and multiplied by the appropriate dilution factor to give gghnl. All samples were 
analysed in duplicate. 
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Z7 Sodium dodecyl sulfate polyactylamide gel electrophoresis (SDS- 
PAGE) and Western immunoblotting 
The solutions for SDS-PAGE including formulation of stacking gels, separating gels 
and electrophoresis buffer are shown in Appendix 3. 
2.7.1 Protein sample preparation and gel electrophoresis 
7.5 % or 12.5 % separating mini-gel was made and overlaid with isopropyl alcohol to 
give a flat surface. Once the separating gel had polymerised, the isopropyl overlay was 
removed and the separating gel surface rinsed with distilled water. 5% stacking gel was 
layered on top of the separating gel, and a comb with the required number of wells was 
carefully inserted. When polymerisation had occurred, the comb was removed, leaving 
behind the sample wells. The wells were then covered with electrophoresis running buffer. 
Protein samples from myornetrial. tissue lysates or cultured myometrial smooth muscle 
cells (40-50 pg) were prepared. Laemn-Ji buffer (2x) containing 0.125 M Tris-HCL pH 6.8, 
4% SDS, 10 % 2-mercaptoethanol, 20 % glycerol and 0.004 % bromoPhenol blue tracking 
dye was added to the samples at 1: 1 (VN) dilution. Samples were mixed, heated for at least 
5 min at 95 T and collected by a brief centrifugation. Samples and standard markers were 
loaded into the wells and subjected to electrophoresis in a mini-PROTEAN 11 cell according 
to the method of Laemmli (1970). The gel was run at 30-35 mA until the tracking dyes 
reached the base of the gel. The gel was removed and proteins from the separating gel 
transferred onto nitro-cellulose membranes using an electroblotting method. Semi-dry 
blotting was found to be less efficient, therefore, the wet blotting with a transfer buffer 
containing methanol (Towbin et aL 1979) was the system used in preference for transferring 
proteins in this thesis. 
2.7.2 Western Blotting: wet blotting system 
Approximately 5 min prior to finishing the electrophoresis, the nitro-cellulose 
membrane (0.45 jim) purchased from Schlicher & Schuefl and six pieces of Whatman 3MM 
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filter papers were cut to the size of the separating gel and pre-soaked in freshly prepared 
transfer buffer (see Appendix 3). This prevents air bubbles becoming trapped in the 
membranes. One of the comers of membrane was labelled to orientate the samples. A clean 
tray containing transfer buffer was prepared and the cassette to hold the gels was placed in 
the tray. A sponge pad was centred on the black side of the cassette (cathode) and air 
bubbles were removed from the sponge. Three pieces of Whatman filter papers were placed 
on top of the sponge pad. Air bubbles were removed by rolling a pipette over the papers. 
After samples had undergone electrophoresis, the stacking gel and unused gel were trimmed 
and the separating gel soaked in transfer buffer for 15 min to remove electrophoresis buffer 
salts and reduce swelling of the gel. The nitro-cellulose membrane was then placed smoothly 
on the gel (label toward gel). The gel together with membrane were carefully lifted up and 
placed on the filter papers in a cassette. Air bubbles were removed by gently squeezing. 
Three more filter papers were placed on the membrane followed by another sponge pad. 
The bubbles were removed by carefully rubbing or pressing. The other side of the cassette 
was covered and the cassette locked. The cassette and the cooling system supplied with the 
apparatus, in this case, frozen water in a container were placed into a chamber. The 
chamber was then filled with cold transfer buffer, and the system (Bio-Rad wet blotting) run 
at 100 V for 60 min. After transfer, the gel was stained with Coomassie blue and the 
membrane was stained with Ponceau-S to check the efficiency of the transfer. Ponceau-S 
was washed away with Tris-buffered saline (TBS) or PBS. The immobilised proteins on the 
membranes were then detected using immunoblotting analysis. The membranes can be 
stored at this stage by air-drying and kept at -20 'C. 
Z8 Immunoblotting and enhanced chemiluminescence system (ECL) 
After transfer, the membrane was blocked overnight in TBS (TBS: 10 mM Tris-HCI, 
150 mM NaCL pH 8) containing 5% non-fat dried milk. The membrane was rinsed with 
two changes of TBST (TBS and 0.05 % Tween-20). The membrane was incubated at room 
temperature with an appropriate primary antibody diluted in TBST containing 1% non-fat 
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dried milk for the indicated time as shown in Table 1. Following three 15-min washings with 
TBS, the specific secondary antibody conjugated to horseradish peroxidase in TBST was 
applied to the membrane at a dilution of 1: 2500 for the time indicated in Table 1. The 
membrane was then washed three times with TBST. AR procedures were performed on a 
shaking platform at room temperature (20-22 'C). Following antibody incubation, the 
excess buffer from the washed membranes was drained. The enhanced chemiluminescence 
reagents from Amersham were mixed in 1: 1 dilution and added to cover the membranes. 
The incubation time was exactly I min. The excess reagents were drained from the 
membrane and the membrane was wrapped in cling film. All air bubbles were removed. The 
membrane was placed in the film cassette, protein side up. The following steps were carried 
out in a photographic dark room illuminated by the red light. X-ray film was placed on the 
membrane. The cassette was closed and fihn was exposed for 15 sec. The first fihn was 
developed immediately to estimate the exposure time for the next films. The molecular mass 
of protein was estimated by comparing the immunoreactive band to the standard makers on 
the membrane from the same blot. The schematic representation of Western immunoblotting 
is shown in Figure 2.2. 
Table 1. The concentrations and incubation times of primary and secondary 
antibodies used for immunoblotting analysis 
Primary antibody Concentration and Secondary antibody Dilution and 
incubation time incubation time 
TGFP receptor type 1 0.5 gg/niI, 2h and Goat anti-rabbit 1: 2500,1 h 
(TPRI) 30 min 
TGFP receptor type 11 0.5 ptg/mI, 2h and Goat anti-rabbit 1: 2500,1 h 
(TORII) 30 min 
TGFP receptor type 111 0.5 pg/niL 2h and Donkey anti-goat 1: 2500,45 min 
(TPRIII) 30 min 
Interleukin- I receptor I pgha 2h and Goat anti-rabbit 1: 2500,1 h 
type I QL- I RI) 30 min 
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Interleukin-8 receptor 
type B (IL-8RB) 
0.5 pghnl, 2h and 
30 min 
Goat anti-rabbit 1: 2500,1 h 
Cyclo-oxygenase-2 
(COX-2) 
0.5 pg/mL 2h and 
30 min 
Donkey anti-goat 1: 2500,45 min 
c-Fos I [ighnL 2h Goat anti-rabbit 1: 2500,1 h 
c-Jun 0.5 pg/rnl, 2h Goat anti-rabbit 1: 2500,1 h 
GP 1: 1000 Goat anti-rabbit 1: 2500,1 h 
Ga. 1: 1000 Goat anti-rabbit 1: 2500,1 h 
Gai 1: 1000 Goat anti-rabbit 1: 2500,1 h 
The primary antibodies except G-proteins sub-units and HRP-conjugated donkey anti-goat 
were purchasedfrom Insight Biotechnology Ltd. G-protein sub-units were obtainedfrom 
NEN Life Science products, Inc. HRP-conjugated goat anti-rabbit or mouse are purchased 
from Dako Ltd. 
Z9 Quantification of immunoreactive bands 
Band intensities were evaluated by densitometric scanning using a GS-690 densitometer 
and analysed with Multianalyst software from Bio-Rad Laboratory. All assay conditions 
such as reagent concentrations and incubation time were controUed in order to standardise 
procedures. In spite of standardisation, differences between blots occurred. Therefore, the 
intensity values obtained from non-pregnant myometrium or control cells were set at 100 %. 
It is possible to obtain an esthnate of the variability of the expression in the non-pregnant 
myometrium or control cells by comparing these samples on the same gel. This variability is 
illustrated by the error bar on the 100 % level for each of the experiments. Data were 
obtained under conditions where a linear relationship existed between the amounts of 
protein loaded and the intensity of the inimunoreactive signals as shown in Figure 2.3. 
Linearity between amounts of Protein and immunoreactivity was demonstrated for TPRI, 
ILI-RI and IL-8RB. This relationship was approximately linear up to 90 gg of protein per 
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lane. Data in each study represents the mean values of at least four determinations from four 
different samples. 
Methods 
Myometrial lysates or cultured 
myometrial smooth muscle cells 
SDS-PAGE 
Electrobloffing 
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I 
Quantitative analysis 
densitometry with 
image analysis 
Nitro-ceHulose membrane 
Immunodetection with ECL 
specific antibody HRP- 
conjugated 
Figure 2.2 Schematic representation of Western immunoblot analysis 
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Figure 2.3 Linearity between the amounts of protein and intensities of immunoreactive 
signal for TPRI, IL-I III and IL-81113 in myometrial tissue K-sates. 
A. Top panel: Western blot illustrating the expression of TPRI prepared from non-pregnant 
myometrium. Bottom panel: the intensity level of TPRI against different amounts of protein. 
B. Top panel: Western blot illustrating the expression of IL-IRI prepared from non-pregnant 
myometrium. Bottom panel: the intensity level of IL- I RI against different amounts of protein. 
C. Top panel: Western blot illustrating the expression of IIARB prepared from non-pregnant 
myometrium. Bottom panel: the intensity level of IL-8RB against different amounts of protein. 
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Z10 TGF, 61 immunoassay 
Steady-state levels, of TGFPI in myometrial lysates and cell culture medium after 
treatment were measured using enzyme-linked immunosorbent assay (ELISA) kits from 
Amersham. 
2.10.1 Principle of the assay 
As shown in Figure 2.4, antibody to TGFPI was pre-coated onto micro-titre wells. 
Standards and samples were added into the wells. Any TGFPI present was bound to the 
wells and other unbound components were washed away. Antibody to TGFP I was added to 
the wells to sandwich the bound TGFP. The biotinylated second antibody and 
streptavidin/peroxidase were added after several washing steps. Peroxidase activity was 
determined by adding substrate. Colour was developed in proportion to the amount of 
TGFP bound in the first step. The colour reaction was stopped by the addition of acid 
solution and the intensity of the colour was read at 450 nnL The concentrations of TGFP1 
in the samples were then read from a standard curve. 
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Figure 2.4 Schematic representation of a sandwich ELISA 
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2.10.2 Sample preparation 
Myometrial tissue lysates from each subject in the different groups as described in 
section 2.11 were prepared (see section 2.2). Culture medium to be assayed (from section 
2.4) was centrifuged at 1000 g for 10 min at 4 'C to remove particles. Aliquots of clear 
supernatant were kept at -70 ' C. In this thesis, myometrial cells were grown in culture 
medium containing serum, which may contain high levels of TGFP L Therefore, the culture 
medium from control cells was collected to determine the basal levels of TGFP 1. 
2.10.3 Activation procedures 
TGFP I is secreted from cells as a latent complex. To bind to the cell surface receptors 
in vivo it is activated. In vitro, the active form of TGFP I was prepared by acid treatment 
followed by neutralisation as described below. All reagents used in the preparation of 
standards and in the TGFPI assay are shown in Appendix 4.200 pl of hydrochloric acid 
(I M) was added to I n-A of myometrial lysates and culture medium from both control and 
treated-cells. The lysates and medium were mixed well and incubated for 10 min at room 
temperature. The pH values of the lysates and medium were checked and adjusted to a pH 
of 1-2. The acidified samples were neutralised with 200 gI of 1.2 M NaOII/0.5 M BEPES, 
mixed and were adjusted to pH 7-8. The activated culture medium samples were further 
diluted (1: 2) with assay buffer (see Appendix 4). Because of activation procedures, the 
dilution of myometrial lysates was 1.4 and that of culture media was 2.8. 
2.10.4 Preparation of standards 
Clean polystyrene tubes were labelled 1000,500,250,125,62.5,31.3 and 15.6 pg/ml. 
2 mil of assay buffer was added into 1000 pg tube and I n-A into each of the other tubes. 
100 pl of TGFP I standard (10 ng) diluted in 500 gl of reconstitution reagent was added 
into the 1000 pg tube. Thus, the concentration of TGFP I in this tube was 1000 pghnl. 
Serial dilutions of this were made as shown below. 
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1 ml 1 ml 1 ml 1 ml 1 ml 1 ml 
Jý ffNt Jýý> ff5ýý ff, ýý 100 ýtl of std. 
Standard 1000 500 250 
(10 ng/500 pl) 
125 62.5 31.3 15.6 pg/ml 
2.10.5 Assay procedures 
The samples were assayed in duplicate and the procedures are shown in Table 2. All 
reagents used are shown in Appendix 4. 
Table 2. ELISA protocol for TGFPI 
Blank tube Standard tubes Sample tubes 
(Zero Std) 
1. Assay buffer 100 ILI - 
Standard - 100 PI - 
Samples 100 gI 
2. Cover plate, incubate at 37 'C for I h. 
3. Wash all wells 4 times with wash buffer and blot the plate by tapping briskly on 
soft paper. 
4. Diluted-detection antibody 100 gI 100 100 PI 
5. Incubate at 37 'C for 1h and repeat step 3. 
6. Diluted biotinylated second 100 PI 100 PI 100 gI 
antibody 
7. Incubate at 37 *C for Ih and repeat step 3. 
8. Diluted streptavidin-IIRP 100 P1 100 gI 100 gl 
conjugated 
9. Incubate at 37 0C for Ih and repeat step 3. 
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Con't 
10. TMB substrate 100 ý11 100 ýd 00 ýd 
11. Incubate at room temperature for 30 min. 
12. Stop solution 1 100 ýtl 100 [LI 100 ýd 
13. Determine optical density (OD) at 450 nm within 30 min. 
2.10.6 Calculation of results 
The mean OD of each sample and standard was calculated. The mean OD of the zero 
standard was subtracted from each mean value of sample and standard. A linear dose- 
response standard curve was constructed by plotting a log/log plot of mean OD (y axis) 
against standard TGFPI concentration (x axis). The values of samples were read directly 
from the standard curve or calculated from the linear regression analysis formula obtained 
from the curve. The concentrations of total TGFPI in myometrial. tissues are reported as 
pg/g tissue wet weight. For cultured cells, the total amount of TGFP I in the culture media 
in each well was divided by the total amount of protein from the same well. The total levels 
of TGFP I were then reported as the mean of four batches of cefls and expressed as pg/ýtg 
cell proteirL 
2.11 Intracellular cAMP enzyme-immunoassay 
Levels of intracellular cANT in cultured cells were measured using cAMP enzyme 
immunoassay kits from Amersham. 
2.11.1 Sample preparation 
After forskolin treatment, the culture medium was aspirated. The cells in each well 
were lysed in 300 gl of lysis reagent IB supplied by the manufacturer. The plates were 
placed on a plate shaker and shaken for 10 min to facilitate cell lysis. Lysed cells were 
processed in=ediately for the inimunoassay or kept at -20 T until used. 
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2.11.2 Preparation of working standards 
Polystyrene tubes were labelled 12.5,50,100,200,400,800 and 1600 finol. 500 pl of 
lysis reagent IB was pipetted into all tubes. Stock standard (32 pmol/ml) at a volume of .7ý 
500 ýtl was pipetted into the 1600 finol tube. The standard solution was mixed thoroughly 
and 500 gl of standard from the 1600 finol tube was transferred to the 800 finol tube. The 
serial dilution steps were repeated with the remaining tubes and a 100 ýd allquot from each 
dilution provided eight standards from 12.5-1600 finol. 100 pl of stock standard was used 
as the top standard concentration of cAND (3200 fmol). 
2.11.3 Assay procedures 
The assay was performed in duplicate and the protocol is shown in Table 3. Reagents 
and reagent preparations are shown in Appendix 5. 
Table 3. Enzyme immunoassay protocol for cAMP 
Blank 
Tube (B) 
Non-specific 
binding tube 
(NSB) 
Zero standard 
tube (B. ) 
Standard 
tubes 
Sample tubes 
Lysis reagent IB - 100 [d 100 gI 
Lysis reagent 2B - 100 gI - - 
Standards - - 100 gI - 
Samples - - - 100 gl 
Antiserum 100 PtI 
I 
100 gI 100 gI 
Cover plate and incubate at 4 'C for 2h 
Peroxidase- 
conjugate 
50111 '0"1 50 pI 50,, l 
Cover plate and incubate at 4 'C for I h, aspirate 
and carefully wash all wells four times with 400 lil of wash buffer 
TMEB substrate 1 150 pI 1 150 pI 1 150 gI 1 150 gI 1 150 PI 
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Con't 
Cover plate and incubate on a shaker 
for exactly Ih at room temperature 
IM suffiiric acid 1 100 ý, I 100 PI 100 gi 100 gi 100 gi 
Detern-fine the optical density at 450 nm within 30 min 
2.11.4 Calculation of results 
The mean OD of each sample and standard was calculated. The percentage bound for 
each standard and sample was calculated using the following formula: 
% B/B. = (standard or spMple OD-NSB OD) x 100 
(zero standard OD-NSB OD) 
A standard curve was generated by plotting % B/B. as a function of the log cAW 
concentration. Thus, % B/B,, was plotted (y-axis) against finol cAMP/well (x-axis) on semi- 
log graph. The concentrations of samples were read directly from the standard curve. The 
mean of intracellular cAND concentration (triplicate experiments) from each batch of cells 
was expressed as finol/pg cell protein. 
2.12 Statistical analysis 
Data are expressed as mean + standard error of the mean (SEM). Comparisons of means 
between two groups were analysed with Student's t test. Multiple comparisons were 
performed using analysis of variance (ANOVA) with a Bonferroni correction. Where 
appropriate, Kruskall Wallis was used and indicated in the figure legend. P values < 0.05 
were considered significant. Asterisks (* and) indicate the levels of significance. 
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Chapter 3 
Gestational changes in the levels of TGFPI and TGFO receptor types I 
and 11 in the human myometrium 
The ability of the myometriurn to contract efficiently at term may be determined by a 
number of specific contraction associated proteins (CAPs) that control the mechanism of 
contraction (Lye, 1996). By triggering the synthesis of these proteins, the myometrium. can 
be transferred from a state of overall quiescence into one primed for activation (Lopez 
Bernal et aL 1995). As term proceeds, a number of CAPs such as oxytocin receptors 
(Kimura et aL 1996), gap junctions (Chow & Lye, 1994), ion channels (Boyle & Heslip, 
1994; Mershon et aL 1994) and the ryanodine sensitive intracellular Caý' release 
mechanism, RyR2 (Awad et aL 1997), are increased within the human myometrium. The 
nature of the signals that trigger the synthesis of these CAPs in vivo is not known. It has 
been shown that RyR2 is up regulated by TGFPI in cultured myometrial smooth muscle 
cells (Awad et aL 1997). This leads to the idea that TGFP I could play a similar role in the 
activation of RyR2 gene in the process of myometrial preparation in vivo. 
TGFP is a multifimctional cytokine, which exerts its actions via receptor Types I, Type 
II and Type III (Massague, 1992; Massague & WeisGarcia, 1996). The intracellular 
processes linking TGFP and TGFP receptor activation can be complex. One action of TGFP 
is the activation or inhibition of gene expression (Heldin et aL 1997). If TGFPl plays a 
similar role in the activation of specific CAP genes in the pregnant myometrium, then it is 
important to demonstrate the presence of TGFP I and TGFP receptors in the myometrium. 
The present experiments were performed to explore the idea that the TGFP system might 
form part of a signalling cascade in vivo. 
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3.1 TGFfl receptor expression 
Immunohistochemistry was used to determine whether TGFP receptors were expressed 
in uterine smooth muscle cells in myometrial samples collected from non-pregnant, term 
pregnant non-labouring and term spontaneous labouring women. Figure 3.1 (A, B and Q 
show photornicrographs of tissue sections of human myornetrium from non-pregnant, 
pregnant-non labouring and spontaneous labouring women respectively. Each section 
illustrates (a) control sections (b) sections stained for type I TGFP receptor (TPRI) 
(c) staining for type II TGFP receptor (TPRII) and (d) staining for type III TGFP receptor 
(TPRIII). In each of the three patient groups, TGFP receptor types I and II were detected in 
the myometrial. smooth muscle cells. No expression of type III TGFP receptor was detected 
in any of the tissues studied. 
Western immunoblotting was subsequently employed to quantitate the relative amounts 
of TGFP receptors expressed in tissue lysates prepared from the different myometrial 
tissues. Figure 3.2A shows nitro-cellulose blots stained with antibodies to TGFP receptor 
types I and II in non-pregnant, term pregnant non-labouring and spontaneous labouring 
tissues respectively. Blots were also incubated with an antibody to the G protein sub-unit, 
GP, as a loading control as the expression of this G-protein sub-unit remains constant in the 
human myometrium during pregnancy and labour (Europe Finner et aL 1994). As in Figure 
3.1, the protein for TGFP receptor types I and II were detected in all samples but no protein 
corresponding to TGFP receptor type III was found. The relative expression of receptors in 
each tissue was analysed using a scanning densitometer. The data for receptor types I and II 
expression in the myometrial tissues after normalising for loading (using the GP) are shown 
in Figure 3.2B. The levels of TGFP receptor types I and 11 expression in non-pregnant 
samples were arbitrarily assigned as 100 %. The amounts of receptor in term pregnant non- 
labouring tissues and spontaneous labouring myometrium are expressed relative to this 
value. The expression levels of TGFP receptor types I and II were significantly increased by 
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168 + 19 % (n = 6) and 162 + 22 % (n = 7) in term pregnant non-labouring tissues (P < 
0.05) compared to those in non-pregnant myornetrium. The expression of both receptor 
types obtained from term spontaneous labouring myornetrium. were 93 + 12 % (n = 6) and 
85 + 11 % (n = 7), respectively. These values were significantly lower than those in 
pregnant non-labouring tissues (P < 0.01) which suggest that there is less protein for both 
receptor types I and II in spontaneous labouring myornetrium. 
In a ffirther series of experiments, the relative levels of TPRI expression were also 
compared in non-contractile myometrial samples obtained at 31-35 weeks and those 
obtained from term pregnant-non labouring samples. Figure MA demonstrates a Western 
blot of TPRI in myometrial tissue lysates from three pre-term (lane 1-3) and three term non- 
labouring myometrial samples (lane 4-6). Figure 3.313 shows the mean data of TPRI 
expression analysed from five pre-term and seven term myometrial tissue samples. The 
expression of TPRI obtained from pre-term myometrium was 53 ±7%. The results show 
that TPRI expression in myometrium is significantly lower in pre-term compared to term 
pregnancy (100 %, P<0.0 1). 
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Figure 3.1 Localisation of TGFP receptors in uterine smooth muscle cells in the human 
myometrium. 
Tissue sections from non-pregnant, pregnant non-labouring and spontaneous labouring 
myometrium are illustrated (A, B and C respectively, which is representative of two 
experiments). For each tissue a control, without TGFO receptor antibody and counterstained 
only with haernatoxylin is shown (a). The presence of TGFP receptor types 1,11 and III are 
illustrated in sections (b), (c) and (d) respectively. Positive staining is represented by the 
distinctive brown colour within the myometrial smooth muscle cells. This experiment was 
repeated twice in each sample group (n = 2). 
trld 
Results 
(a) 
(b) 
(c) 
A 
'a 
BC 
i .V".. 
I. 
" 
". i. 
" 
!. 
' 
: - . '. % *-S '" 
-SI" 
%_"'" 
- 
S. .  ". -- - S-e". 
S"" 
'p 
S_S. 
.. 5'.. ". " 
'*5 'F -- 
S 
'. 
._:: 
- "1 
411 
(d) jI1 
V4 
. ýI Z.: ', 
, 
Apa 
Figure 3.2 Western-immunodetection of TGFP receptor v-pes 1.11 and III in human 
myometrium 
A. Western blots illustrating the expression of -1-61ji receptor týpes 1.11 and III in tissue 
lysates prepared from non-pregnant (NP). pregnant non-labouring (PNL) and spontaneous 
labouring myometrium (SL). The expression of the G-protein GP is also shown. This protein 
does not change during pregnanc-y and can be used as a loading control. Molecular weight 
markers are expressed as kilodaltons (kD). 
B illustrates analysis of six to seven separate myometrial lysate preparations from the different 
patient groups. Relative levels of TGFP receptor in each tissue were determined as the ratio of 
TGFP receptor protein/GP protein measured by densitometry. The values shown are mean ± 
SEM. and expressed relative to the receptor levels ot'non-pregnant rný o metrium ( 10()(, o). *. P< 
0.05. **, P<0.01. 
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Figure 3.3 The expression of TPRI in pregnant myometriurn at 31-35 and 38-40 weeks 
of gestation 
A Western blots illustrating the expression of TýRl in lysates prepared from myornetrial 
tissues from pre-term non-labouring (31-35 weeks) and pregnant term non-labouring (PNL, 
38-40 weeks) myometrium. 
B illustrates analysis of five samples from pre-term and seven samples from term pregnant 
myometrium. Relative TPRI receptor levels were determined by densitometry. The levels 
determined in each blot for the 38-40 week samples were arbitrarily set at 100% and the 
levels of expression in pre-term samples expressed as a relative change. The values shown 
are mean + SEM. * *, P<0.0 1 by Student's t test. 
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3.2 TGFfll expression in the myometrium 
Because TGFP receptors were detected in the myometrium at the end of pregnancy and 
in spontaneous labouring myometrium, it was then important to establish whether TGFP 
could be measured in these tissues. The presence of both cytokine and receptor are essential 
if this system is to have a physiological role. Figure 3.4 illustrates measurements of the 
tissue concentrations of the total TGFP I (latent plus active) in non-pregnant, term pregnant 
non-labouring and term spontaneous labouring myornetrium using ELISA. The amount of 
TGFPI was increased from 334 + 10 pg/g of tissue wet weight in non-pregnant 
myometrium. to 534 + 73 and 674 + 106 pg/g of tissue wet weight in pregnant non- 
labouring and spontaneous labouring myometrium. (n =3 in each group), respectively. 
However, these values were just outside the range of statistically significant difference 
between groups because of the small sample size (P = 0.06). 
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Figure 3.4 TGFPI in human myometrium 
Measurements of the total concentrations of TGýO I in non-pregnant. pregnant non-labouring 
and spontaneous labouring myometrium. Concentrations are expressed as pg/g of tissue wet 
weight. Values are mean + SEM (n =3 for each patient group). Data were analysed with 
Kruskall Wallis. 
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3.3 Discussion 
The ma or observations in this study are 1) that the levels of TGFP receptor types I and 
II changed with pregnancy and 2) that the levels of TGFP1 in the myometrium are not 
significantly altered. These observations are analogous to the change reported in the levels 
of oxytocin receptor prior to labour without any change of oxytocin levels. Thus, it may be 
a general principle that the myometrium regulates its functions at the level of surface 
membrane receptors rather than by endocrine or paracrine hormone levels. These 
observations support the idea that TGFP1 may operate as an autocrine signal in the 
myometrium. The data are consistent with the TGFP I system being involved in two aspects 
of myometrial physiology. Firstly the TGFP1 system may be involved in the preparation of 
the myometrium for labour. It is possible that a rise in TGFP receptors in the myometrium 
preceding spontaneous labour may increase the responsiveness to TGFPI. These changes 
may function within a cascade of events within the last few weeks of pregnancy to facilitate 
the activation of specific myometrial genes associated with contractility. Secondly the down 
regulation of TGFP receptor during labour may influence contractility. The mechanisms by 
which TGFP receptors are regulated during pregnancy and labour remains to be elucidated. 
Furthermore the physiological role of TGFP system remains to be proven. 
In this investigation, the levels of TGFP I were assayed using acid hydrolysis and only 
total levels of TGFP I (latent + active) were determined. Generally, it is only active TGFP I 
that can bind to the receptor. Although we could not detect any changes in total TGFP I 
levels, it is possible that there could be a change in the amount of active TGFP I produced in 
the myornetrium. Thelotal levels of TGFP I may be increased but only three samples were 
studied. With such small numbers we could not exclude anything but a large change. With 
this perspective further experiments would be desirable to address this specific question. 
Alternative approaches for the determination of the amount of TGFP1 expression such as 
Western analysis for the protein or RT-PCR for RNA determination was considered. 
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Bioassay techniques were also considered to detemiine the amount of active TGFP I in the 
future experiments. 
A number of other CAPs such as oxytocin and endothelin receptors are found to be 
increased in the myometrium at term (Kimura et al. 1996: Wolff et al. 1996). Conversely, 
the number of angiotensin receptors is decreased as term approaches (Matsumoto et al. 
1996). Thus it would appear that a common mechanism that could influence myometrial 
function would be to regulate 'up' or 'down' the expression of essential receptors. In this 
way, the myometrium, can alter its function from a weakly contractile and poorly excitable 
tissue to one capable of powerful co-ordinated contractions. 
TGFP has been postulated to be a potential regulator of many functions in the non- 
pregnant uterus and in early pregnancy. It has been reported that levels of expression of 
TGFP receptors and TGFP change during the menstrual cycle (Chegini et aL 1994). The 
role of oestrogen and progesterone has been suggested to account for these variations in the 
human uterus (Chegini et aL 1994). Human myometrial cells in vitro have been shown to 
synthesise and release TGFP (Chegini et aL 1996; Tang et aL 1997). In turn, it has been 
shown that the amount of TGFP synthesised can be increased by gonadotrophin releasing 
hormone (GnRH), 17P oestradiol and medroxyprogesterone acetate (Chegini et aL 1996). 
TGFP has also been reported in the murine uterus at implantation, where it may be 
involved in synchronising embryonic development (Tamada et aL 1990; Das et aL 1992). In 
the non-pregnant ovariectomised mouse uterus, the expression of TGFO can be transiently 
increased by the injection of oestrogen (Das et aL 1992). It has been reported in other cell 
types in animals that the expression of TGFP receptors can be influenced by several 
hormones (Cochet et aL 1988; Kim et aL 1996). For example, ACTH up-regulates TGFP 
receptors in bovine adrenocortical cells (Cochet et aL 1988) and androgens affect receptor 
expression in the ventral prostate in rat (Kim et aL 1996). 
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Taken together these observations indicate that the TGFP signalling system is under 
hormonal regulation. This may also be the case in late human pregnancy. TGFP receptors 
are however unlikely to have a role in the direct activation of contractions. It is more likely 
that they are associated with activation of myometrial cell growth and differentiation in 
preparation for parturition. Thus, it can be speculated that the myometrium. is prepared for 
term as a result of a cascade of events involving the sequential expression of signals, 
receptors and contraction associated proteins. 
The activation of the TGFP signalling pathway involves binding of TGFP to the type II 
receptor, resulting in the formation of a complex between type I and type II receptors. The 
consequence of this binding is the phosphorylation of the type I receptor (Heldin et aL 
1997; Massague & WeisGarcia, 1996). However, in some instances TGFP can activate cells 
that lack detectable level of type II receptor (Chen et aL 1993) via activation of type I 
receptors alone (Wieser et aL 1995). It has been shown that a MAD-related family of signal 
transducers is required for intracellular events in the TGFP pathway (for reviews see 
(Wrana, 1998; Derynck & Feng, 1997)). This includes the Drosophila Mothers against dpp 
gene (Mad ) and its honiologue, Sma in C elegans. In human, a group of vertebrate 
honiologues of Sma and Mads, designated Smads, in the cytoplasm is known to be a 
potential signalling mediators of TGFP (Wrana & Pawson, 1997; Heldin et aL 1997). Other 
proteins using the type I receptor such as FK506-binding protein may also modulate 
receptor signalling (Heldin et aL 1997; Massague & WeisGarcia, 1996). However, the 
mechanisnLs underlying the TGFP signals in the human myornetrium. are still unknown. 
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Chapter 4 
Complex interactions between sex steroids and cytokines in the human 
pregnant myometrium: evidence for an autocrine signalling system at 
term pregnancy 
Cytokines have been thought to play a role not only in the mechanisms of pre-term 
delivery but also normal labour (Romero et aL 1990; Steinborn et aL 1996). Recently, there 
have been several reports showing that the concentrations of tumour necrosis factor-cc 
(TNFcc), IL-I and IL-8 in the human myometrium are increased towards term (Osmers et 
aL 1995; Kemp et al. 1998). Thus, it can be hypothesised that a cytokine cascade is 
involved in the preparation of human myometrium for term. 
It has been shown that there are two types of IL-1 receptor (Sims et al. 1989; 
Mcmahan et al. 1991). These are termed IL-1 receptor types I (IL-IRI) and type 11 (IL- 
1RII). IL-IRI has been found in many cell types including endothelium, fibroblast, decidua 
and smooth muscle cells (Sims et al. 1989; Sims & Dower, 1994; Ammala et al. 1997; 
Whittle et al. 1999) and has been considered a signal transducing receptor (Colotta et al. 
1993; Sims et al. 1993). However, there is no data to assess the possibility that the 
myometrium expresses receptors for IL-1. Two types of receptors for IL-8, types A (IL- 
8RA) and B (IL-8RB), have been demonstrated in myometrium before the initiation of 
labour but there has been no estimate of the levels of IL-8 receptor expression (el Maradny 
et al. 1996b). In most cells IL-8 can bind to both receptors and each receptor has different 
functions (Chuntharapai & Kim, 1995). In neutrophils, for example, IL-8RA plays an active 
role in the initiation of neutrophil migration at the site of inflammation. In contrast, IL-8RB 
mediates IL-8 signals outside the inflammatory site (Chuntharapai & Kim, 1995). 
Results 
Because cytokines work through their specific receptors, the first study in a series of 
experiments was to demonstrate whether the human myometrium. expresses IL- I RI and IL- 
8RB receptors and to identify if levels change with gestation. 
4.1 IL-1 and IL-8 receptor expression 
In each series of experiments, the level of expression in the non-pregnant myometrium 
was arbitrarily set to 100 % and changes in term pregnant non-labouring and spontaneous 
labouring tissues expressed relative to these values. Figure UA shows typical Western 
blots using an antibody raised against the IL-1 receptor on samples of non-pregnant, 
pregnant non-labouring and spontaneous labouring tissues. Figure 4.1 B shows accumulated 
data from a densitometric analysis, obtained from eight tissue samples in each group. The 
highest level of IL-IRI expression was found to be in the non-pregnant samples. Compared 
to the non-pregnant tissue, the receptor expression was significant reduced to 71 +8% 
(P < 0.05) and 40 +7% (P < 0.001) in the term pregnant non-labouring and spontaneous 
labouring samples, respectively. There was also a significant difference in the expression 
levels between the pregnant and spontaneous labouring tissue (P < 0.01). 
Figure 4.2A shows an example of a Western blot examining the expression of IL-8RB 
in the same group of myometrial samples. As can be seen in Figure 4.213, in contrast to the 
IL-1 receptor, the expression of IL-8 RB was highest in the term pregnant non-labouring 
samples (196 + 24 % of the non-pregnant level, P<0.0 1). In the spontaneous labouring 
myometrium, the expression of IL-8RB was found to be reduced to 59 + 10 % compared to 
the non-pregnant control but this is not statistically different. However, this level was 
significantly lower than the level obtained from the pregnant non-labouring myornetrium. 
(P < 0.001). 
As shown previously in chapter 3, TGFP receptors change during late pregnancy, 
raising the question '*hat are the signals in the cytokine cascade that influence the 
expression of TGFP receptors? ". It has been reported in many cell types that cytokines can 
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affect the expression of other cytokines and cytokine receptors (Balkwill & Burke, 1989; 
Arai et aL 1990; Foxwell et aL 1992). Cytokines can also regulate the expression of their 
own receptors. It is conceivable that complex cytokine interactions may take place in the 
human myometrium. It is not possible to investigate interactions between cytokines and the 
expression of other cytokines and receptors during pregnancy in vivo. Therefore, a series of 
experiments were carried out in cultured human myornetrial smooth muscle cells isolated 
from non-pregnant myometriurn to determine the possibility that IL-1 and IL-8 might 
influence the expression of TGFP1 and TPRI. The possible interactions between these 
cytokines were also investigated. 
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Figure 4.1 Western immunodetection of IL-I receptor type I (11,1-RI) expression in the 
human myometrium 
A. Westem blots illustrating the expression ot' ILI-RI in tissue ]-sates prepared from non- 
pregnant (NP), pregnant non-labouring (PNL) and spontaneous labourIng myometriurn (SL). 
B illustrates analysis of 8 NP. 8P and 8 SL tissue samples. Relative IL-1 receptor levels in 
each tissue was determined by densitometry. The levels determined in each blot for the NP 
samples were arbitrarily set at 100% and the levels of expression in the P and SL samples 
expressed as a change relative to the NP level. The values shown are mean + SEM. *. P<0.05; 
**, P<0.01; ***. P<0.001. 
Figure 4.2 Western immunodetection of IL-8 receptor "-pe B (IL8-RB) expression in the 
human myometrium 
A. Western blots illustratig the expression of 11-8-RB in tissue Iýsates prepared from non- 
pregnant (NP), pregnant non-labouring (P) and spontaneous labouring myometrium (SL). B 
illustrates analysis of 7 NP. 7P and 7 SL tissue samples prepared from different patient 
groups. Relative IL-8 receptor levels in each tissue were determined by densitometry. The 
levels determined in each blot for the NP samples "ere arbitrarily set at 100% and the levels of 
expression in the P and SL samples expressed as a change relative to the NP level. The values 
shown are mean + SEM. * *, P<0.0 1. ***. P<0.00 1. 
I 
Figure 4.1 Western immunodetection of 11A receptor type I (ILI-RI) expression in the 
human myometrium 
A. Western blots illustrating the expression of' ILI-RI in tissue lysates prepared from non- 
pregnant (NP), pregnant non-labouring (PNL) and spontaneous labouring myometrium (SL). 
B illustrates analysis of 8 NP, 9P and 9 SL. tissue samples. Relativc 11A receptor levels in 
each tissue was determined by densitometry. The levels determined in each blot for the NP 
samples were arbitrarily set at 100% and the levels of expression in the P and SI. samples 
expressed as a change relative to the NP level. The values shown are mean + sEm. *, P<0.05; 
**, P<0.01; ***, P<0.001. 
Figure 4.1 Western immunodetection of IL-1 receptor type 1 (ILI-RI) expression in the 
human myometrium 
A. Western blots Illustrating the expression of ILI-RI in tissue lysates prepared from non- 
pregnant (NP). pregnant non-labouring (PNL) and spontaneous labouring myometrium (SL). 
B illustrates analysis of 8 NP, 8P and 8 SL tissue samples. Relative IL-1 receptor levels in 
each tissue was determined by densitometry. The levels determined in each blot for the NP 
samples were arbitrarily set at 100% and the levels of expression in the P and SL samples 
expressed as a change relative to the NP level. The values shown are mean + SEM. *. P<0.05. 
**. P<0.01, ***, P<0.001. 
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Figure 4.2 Western immunodetection of IL-8 receptor type B (IL8-RB) expression in the 
human myometrium 
A. Western blots illustrating the expression of 11-8-RB in tissue lysates prepared from non- 
pregnant (NP), pregnant non-labouring (P) and spontaneous labouring myometrium (SL). B 
illustrates analysis of 7 NP. 7P and 7 SL tissue samples prepared from different patient 
groups. Relative IL-8 receptor levels in each tissue were determined by densitometry. The 
levels determined in each blot for the NP samples were arbitrarily set at 100% and the levels of 
expression in the P and SL samples expressed as a change relative to the NP level. The values 
shown are mean + SI. m. **. P<0.01. ***. P<0.001. 
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4.2 IL-1 and IL-8 effects on TGF, 61 and T, 6RI expression 
To investigate the effect of IL-1 and IL-8 on the expression on TGFPI and TPRI, 
confluent myometrial cells were incubated for 24 h with IL-I or IL-8. Figure 43A shows 
that IL-8 at a concentration of 150 ng/mI significantly increased the expression of TGFP I in 
human myometrial cells from 21.4 + 0.99 to 54.7 + 2.0 pg/ptg protein (P < 0.001). As 
shown in Figure 43B, the expression of TPRI was also induced by IL-8. The level of TPRI 
expression in control cells was set to 100 % and the level of TPRI expression increased to 
152 + 15 % compared to the control ceUs (P < 0.05). IL-1, at a dose chosen to be maximal 
for prostaglandin stimulation in human myometrial cells (10 ng/ml) (el Maradny et al. 
1996a; Todd et al. 1996), significantly increased the total level of TGFPI to 29.5 + 1.1 
pg/pg protein (P < 0.01). At this concentration, IL-I did not significantly influence the 
expression of TPRI compared to that found in the control ceUs. Because IL-8 affected both 
TGFPI and TPRI expression, further experiments were carried out in myometrial ceRs to 
explore the possible interactions between the TGFP and IL-8 signalling systems. 
4.3 Interactions between TGF, 61 and IL-8 
Figure 4.4A shows that the level of expression of IL-8 RB was significantly decreased 
to 84 +3% in myometrial cells exposed to TGFPl (1 ng/n-A) for 24 h compared to the 
control untreated cells (100 %). In contrast, in cells which were exposed to TGFP1, the 
expression of TPRI was markedly increased to 158 + 13 % as shown in Figure 4.413. When 
cells were exposed to IL-8 (150 ng/ml) for 24 h, the expression of the IL-8 RB was found 
to be reduced and the level of expression was 84 +3% as demonstrated in Figure 4.4C. 
Thus, there appears to be a complex relationship between these cytokines and the 
expression of cytokine receptors. 
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Figure 4.3 The effects of IL-I and IL-8 on TGFPI and TPRI expression 
A. Human myometrial smooth muscle cells were incubated with IL- 1 (10 ng/ml) and IL-8 (150 
ng/mI). The total concentration of TGFýl in the culture medium was measured after 
incubation for 24 h. Values are mean + SEM of four experiments from four different tissues 
assayed in duplicate (n = 4) and expressed as pg/ýig protein. B. Myometrial smooth muscle 
cells (50 pg) from control (C). IL-1 and IL-8 treated cells were separated in SDS-PAGE and 
subjected to Western blot analysis with specific antibody to TPRI. The results are expressed as 
means of triplicate measurements of TPRI expression in myometrial smooth muscle cells 
isolated from five different tissue samples. Densitometry data are expressed as a percentage of 
control. *, P<0.05; **. P<0.01; ***. P<0.001 as compared to the control. 
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Figure 4.4 The effect of TGFPI on the expression of IL-8 receptor tý-pe B OL-8RB) and 
the effects of TGFPI and IL-8 on their own receptors. 
A. and B. Mvometrial smooth muscle cells (50 Liu) t'rom control (C) and cells treated 'Aith 
TGFPI, Ing/ml (T) for 24 h were separated in SDS-PAGE and sub jected to Ikestem blot 
analysis with antibodies to lL-8RB and TPRI. The results are expressed as means of triplicate 
measurements of IL-RB andTPRI expression in myornetrial smooth muscle cells isolated from 
four and eight different tissue samples, respectively. 
C. The cells were treated with IL-8 (150 ng/ml) for 24 h. IL-8RB expression from these cells 
(C. control-, T. IL-8-treated cells) was evaluated by Western blot analysis of cell homogenates 
(50 ug). The results are expressed as means of triplicate measurements of IL-8RB expression 
in myometrial smooth muscle cells isolated from four different tissue samples. Densitometry 
data are expressed as a percentage of control. **. P<0.01. 
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4.4 Oestrogen and progesterone effects on TGFPI and T, 6RI expression 
Oestrogen and progesterone undergo a progressive rise throughout pregnancy and 
changes in the level of these steroids have been shown to be associated with human 
parturition (Liu & Rebar, 1999). It has been recognised for some time that progesterone 
acts as a myometrial relaxant, which maintains quiescence during pregnancy (Csapo, 1977). 
Oestrogen, in contrast, increases myornetrial contractility and enhances myometrial 
sensitivity to other substances involved in the mechanism of myornetrial contraction (Lye, 
1996). In the non-pregnant state, the main oestrogen secreted by the developing follicle 
during the menstrual cycle is 170-oestradiol. During pregnancy, the concentrations of this 
hormone increase to about 100 times the non-pregnant value (Pocock & Richards, 1999). 
17p-oestradiol and progesterone have been demonstrated to regulate the formation of 
myornetrial gap junctions (Zhao et al. 1996; Garfield et al. 1999). Thus, it is of direct 
relevance to determine whether these steroids can affect the expression of TGFP I and TPRI 
in myornetrial smooth muscle. 
Data from a series of experiments to explore this idea are shown in Figure 4.5. Figure 
4.5A shows that 170-oestradiol at 10 nN4, the lowest circulating blood levels during 
pregnancy (Andersen et aL 1993), had no effect on TGFOI levels. At 100 nN4 170- 
oestradiol, the concentration of TGFPI was significantly increased from the control level of 
20.7 + 1.3 pg/gg protein to 29.2 + 0.6 pg/gg protein (P < 0.001). Although there was no 
significant difference detected on exposure of cells to a high dose of progesterone 
(200 nM), progesterone at a lower concentration (100 W) significantly increased the level 
of TGFP I to 26.2 + 1.3 pg/jig protein (P < 0.0 1) 
Exposure to 10 nM 17P-oestradiol or 100 nM progesterone had no significant effect on 
the expression of TPRI in cultured myornetrial cells. As shown in Figure 4.513, TPRI 
expression was significantly reduced when the myometrial cells were exposed to 100 nM 
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17P-oestradiol or 200 nN1 progesterone. The percentage reductions following 17p- 
oestradiol and progesterone exposure were 61.4 + 10.5 and 47.8 + 9.5, respectively. 
In vivo it is likely that there may be changes in both steroid hormone levels as well as 
cytokine concentrations. From Figure 4.3, it was shown that IL-I and IL-8 alone 
significantly increased the release of TGFP1 into the culture medium. Figure 4.6 illustrates 
data examining the combined effects of IL-1, IL-8 and 17p-oestradiol. The results show that 
17p-oestradiol at 100 nM reduced the stimulatory effect of IL-8 on the release of TGFP I. 
When IL-I and IL-8 were added simultaneously there was an increase in TGFPI release 
compared to control but this was significantly lower than the stimulation produced by IL-8 
alone (32.8 + 1.7 compared to 54.7 + 2.0 pg/pg protein). Thus, it appears that 17p- 
oestradiol and IL-I can inhibit the stimulatory effect of IL-8 in vitro. The consequences of 
these complex interactions in vivo have yet to be explored. 
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Figure 4.5 The effects of 17p-oestradiol and progesterone on TGFOI and T(; FP receptor 
type I (TPRI) expression 
A. Human rnýonietrial smooth muscle cells were incubated with 17p-oestradiol (10 nm and 
100 nm) and progcsterone (100 nm and 200 rim). 'rhe total concentration of TGFPI in the 
culture mcdium was measured after incubation for 24 h. Values are mean + SEM of four 
experiments from four different tissue samples assayed in duplicate (n = 4) and expressed as 
pg/pg protein. 
13. Myometrial smooth muscle cells (50 pg) from control (C) and treated cells [I 7p-oestradiol 
(FIO and ElOO) and progesterone (PlOO and P200)] were separated in SDS-PAGE and 
subjected to Western blot analysis with a specific antibody to TPRI. The results are expressed 
as means oftriplicate measurements of TPRI expression in myometrial smooth muscle cells 
isolated from five different tissue samples. Densitometry data are expressed as a percentage of 
control. *. P<0.05. **. P<0.01. ***. P<0.001. 
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Figure 4.6. The effects of 170-oestradiol. II. -I. IIA and thcIr cornhinations on TGFOI 
production 
Human mýometrial smooth muscle cells , %ere incubated %%ith 17ji-oestradioi ( 100 nlý, I). IL-1 
(10 ng/ml), IL-8 (150 ng/ml) and their combinations for 24 h. The total concentration of 
TGFPI in the culture medium were measured. Values are mean - SF%I of four experimentg 
from four different tissue samples assayed in duplicate (n = 4) and expressed as pg. ýLg protein. 
P<0.01, ***, P<0.001 (there is significantly different 1) < 0.001 in each group as 
compared to the IL-8-treated cells). 
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4.5 Discussion 
The observations made in this study suggest that the receptor levels for IL-1 and IL-8 
in the myometrium. change with pregnancy. These results support previous observations that 
IL-8 receptors are present in the human myometrium. at term before the initiation of labour 
(el Maradny et aL 1996b). It may be important to note that the patterns of change in 
receptor expression are different for both receptors. IL-1 receptor expression is greatest in 
the non-pregnant tissue, lower in the pregnant non-labouring tissue and lowest in the 
spontaneous labouring tissue. In contrast, IL-8 receptor expression is maximal in pregnant 
non-labouring myometnum and falls in labouring myometrium. The changes in the 
expression of IL-8RB are similar to the patterns of change for TGFP receptors as previously 
demonstrated in chapter 3. Therefore, there appears to be a difference in the timing of 
expression of cytokine receptors. IL-1 and IL-8 levels in the myometrium. have been found 
to increase at parturition (Kemp et aL 1998). Taken together these observations point to the 
possibility that IL-1 and IL-8 play an autocrine role in the human myometrium. The 
particular relevance of the alterations in the expression levels of both cytokines and 
receptors to overall myometrial functioning at term is not known and has yet to be 
established. However, it may be speculated that the changes reflect a complex series of 
autocrine signals taking place within the myometrium. These autocrine signals may form 
part of a physiological cascade of events leading to the differentiation of the myometrium. If 
this were the case the myometrium. would, to a great extent, be able to control its 
development and prepare itself for powerful contraction without overt intervention from 
fetal or other maternal systems. 
There is evidence for the involvement of cytokines in the modulation of uterine function 
in pre-mature labour (see Mazor et aL 1995). The final result of the cytokine activation is an 
increase in the local concentration of prostaglandin, which in turn has complex actions on 
the myometrium and cervix (Nfitchell et A 1991 a; Norwitz et aL 1992; Pollard et aL 1993). 
The resulting strong myometrial contractions, along with cervical softening, can initiate 
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premature labour and subsequent delivery. If the idea of an autocrine physiological 
signalling cascade is correct, then it is not surprising that exogenous cytokines originating 
from leukocytes activated by infection can prematurely activate this cascade with a 
consequence of premature delivery. 
It is therefore important to understand the complexities of these autocrine signalling 
events and the interactions between components, which are termed signalling associated 
proteins (SAPs), in the cascade. As it is not possible to interfere with the pregnant 
myornetrium. in vivo, an alternative approach is to use human myometrial cells in vitro. The 
findings in this study indicate that both IL-1 and IL-8 increase TGFP1 secretion in human 
myometrial smooth muscle cells in culture. The mechanisms involved are unknown. There is 
evidence to demonstrate that binding of IL-8 to IL-8 receptors activates extracellularly 
responsive kinase (ERK), resulting in an increase of c-fos mRNA (Shyamala & Khoja 
1998). The human TGFPI promoter region also contains activator protein-1 (AP-1) sites 
which are composed of c-fos and c-jun genes (Kim et al. 1990; Scotto et al. 1990), thus, 
IL-8 may stimulate TGFP1 production through activating AM site on the TGFP1 
promoter. Post-transcriptional and Post-translational regulation also affects the production 
of some cytokines (Hamblin, 1993). The increase in TGFP I levels in the myornetrial smooth 
muscle cells by IL-1 and IL-8 may result from such regulations. It is also possible that the 
action of IL-1 on TGFP1 may be mediated indirectly via other agents. For example it is 
known that IL- I can increase the production of PG (Todds et al. 1996). PG could therefore 
affect the level of TGFP I production. This possibility was not examined in this thesis. 
A synergism between these two cytokines has not previously been observed and it is 
likely that IL-I can inhibit the stimulatory effect of IL-8 on TGFPI secretion from the 
myometrial smooth muscle cells (see Figure 4.6). Thus, it can be suggested that higher 
levels of TGFPI may be generated in the human myometrial cells in vivo if IL-I and IL-8 
are produced and presented at different times, and in a specific sequence. 
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IL- I and IL-8 also increase the level of TPRI expression although IL-8 appears to be 
more effective than IL- 1. Thus, under these conditions, both cytokines affect the steady 
state level of both TGFPI and its receptor. It has been found in this study that TGFPI 
induces up regulation of its receptor (see Figure 4.413) and inhibits the expression of IL- 
8RB (see Figure 4.4A) in the myometrial cells in vitro. The up regulation of TPRI induced 
by TGFP I has been reported recently in cultured pancreatic epithefial cells in rat (Menke et 
al. 1999). The level of IL-8RB is down regulated by IL-8 (see Figure 4.4C). This IL-8 
induced down regulation of its own receptor has also been reported in other cell types 
(Chuntharapai & Kim, 1995; Ray & Samanta, 1996). One possible interpretation of these 
data would be that IL-8 would be activated at an earlier stage such that IL-8 would 
stimulate TGFPI production and TPRI expression. TGFP would then aid increasing its 
receptor expression providing a positive feedback and contributing to the increase of TGFP- 
induced cellular responses. TGFP would also down regulate the IL-8 receptor, thus, 
decreasing its effectiveness. In this way one cytokine signal would decrease whilst another 
would increase in importance. A Model representing the interaction between the TGFPI 
and IL-8 systems is shown below. 
IL-8 
Cl LL -8R 
TGFPI 
t %+ 
TPRI 
Ný I 
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In human endometrial cells, TGFP1 acts to potentiate the effect of IL-la to increase 
the level of IL-8 expression (Arici et aL 1996c). There is evidence that IL-1 and TNFa can 
regulate the level of IL-8 production in human endometrial. cells in culture, human chorion 
and decidual cells (Dudley et aL 1993; Arici et al. 1996). It is reasonable to hypothesise that 
the levels of IL-8 in human myometrial smooth muscle cells can be increased by IL- I and 
TNFcc. The involvement of IL-8 in the process of cervical dilation has been well established 
(Chwalisz et al. 1994; Osmers et aL 1995) but the crucial role of IL-8 in the myometrium is 
not well understood. However, by using the in vitro model, it can be suggested that 
interactions between IL-1, IL-8 and TGFP1 occurs in the human myornetrium. at term 
before labour begins. The sequence of events in the myometrium, may be initiated when IL- I 
induces IL-8 followed by IL-8 induction of TGFP I and its receptor and finally TGFP I up- 
regulation of the expression of CAP genes such as RyR2 (Awad et aL 1997). TGFPI can 
increase the synthesis of COX2 and endothelin-1 in other cell types (Xu et aL 1997; 
McKenna et aL 1998). Thus, there appears to be a complex interplay between cytokines, 
which can act to promote the expression of SAPs and the expression of CAPs. 
The levels of expression of cytokines can also be regulated by sex steroids. The 
observations in this study confirm that the expression of TGFP I and the TPRI appear to be 
regulated by oestrogen and progesterone but in a different way. This study shows that 
oestrogen and progesterone can induce TGFP1 synthesis in human myometrial cells. 
Progesterone is less effective on TGFP1 synthesis compared to oestrogen. Moreover, no 
increase of TGFP I has been observed at high level of progesterone. In contrast, it has been 
shown that synthetic progesterone, medroxyprogesterone acetate (MPA), increases the total 
level of TGFP I in human myometrial cells to a greater extent than oestrogen (Chegini et aL 
1996). One possibility that may account for the different responses to MIA and 
progesterone in human myometrial cells may be a consequence of the cells metabolising 
progesterone to a form that does not bind to the progesterone receptor (Dombroski & 
MacDonald, 1993). 
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It has been shown that there is no oestrogen response element (ERE) in the TGFP1 
promoter (Kim et al. 1989). However, incomplete estrogen response element-like 
sequences have been reported in the TGFP I gene (as cited by Hering et al. 1995). It might 
be that the increase in TGFPI production by oestrogen is mediated by ERE-like elements. 
Oestrogen is known to up-regulate the expression of c-fos and c-jun genes (Loose-Nfitchell 
et al. 1988; Weisz et al. 1990). Thus, an alternative explanation could be the stimulation of 
TGFPI via the activation of c-fos and c-jun, which will bind to AP-I site on the TGFP1 
promoter. 
The present study has shown that high doses of oestrogen and cytokines alone and in 
combination were more effective in increasing the total level of TGFP1 than was 
progesterone. In this case the effect of oestrogen, IL-1 and IL-8 may act separately in the 
I 
myometriurn or in concert to overcome the effect of a high level of progesterone on TGFP I 
production in vivo. 
In humans, contrast to many animals at parturition, the plasma concentrations of 
oestrogen and progesterone do not fall prior to the onset of labour (Batra & Bengtsson, 
1978; Fuchs & Fuchs, 1984). There is evidence to suggest that TGFP I may act Eke an anti- 
progestin (Casey & MacDonald, 1996a, 1996b). If this is correct then a high level of 
TGFP I in the myometrium. at term may inhibit the actions of progesterone. Thus, inhibition 
of progesterone action, rather than a withdrawal of progesterone, may be involved in the 
changes seen in uterine activity before labour. 
Oestrogen and progesterone also affect the level of TPRI expression. In contrast to the 
stimulatory effect of oestrogen on TGFPI, oestrogen and progesterone act to decrease the 
expression of TPRI in human myornetrial cells. This is in keeping with the observation in 
vivo, that the level of expression of TPRI is reduced in spontaneous labouring myornetriurn 
at a time when the plasma levels of both steroids are high. Thus, the expression of TPRI and 
TGFP1 are regulated in the opposite way by sex hormones in human myornetrium. These 
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data suggest an interaction between endocrine and autocrine systems in the myornetrial. 
cells. It can be concluded from these overall observations that a complex and fine balance 
between cytokine and endocrine networks underlies the physiological process regulating the 
preparation of the human myometrium. for term. 
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Chapter 5 
Myometrial COX-2 expression and identification of synergistic and 
sequential actions of cytokines on TORI and COX-2 expression in human 
myometrial cells in vitro 
There is substantial evidence that prostagandins (PG), which are synthesised from 
arachidonic acid, play a role in the initiation of parturition and the onset of pre-term labour 
(Kelly, 1994). Cyclooxygenase (COX) or prostaglandin H synthase (PGHS) is believed to 
be involved in the initial reaction of PG synthesis (Rosen et aL 1989). It is generally 
accepted that myometrium is the target of PG action rather than the site of PG production 
(Moore et aL 1999). However using immunohistochernical technique, this enzyme has been 
found in the myometrium and localised in the smooth muscle (Zuo et aL 1994). This is 
indicative of the biosynthesis of PG in the myometrium. 
COX- I is the constitutive form, whereas COX-2 is a regulated form of the enzyme (Hla 
et al. 1986; Morita et al. 1995). In situ hybridisation and immunocytochernistry has 
demonstrated that the expression of COX-1 mRNA and protein were lower at term 
compared to pre-term whilst the levels of COX-2 were increased at term. Moreover, COX- 
2 levels were lower during labour compared to that of non-labouring tissue (Zuo et al. 
1994). In contrast to this study, Moore et al (1999) have reported that both COX-1 and 
COX-2 mRNA did not change significantly during gestation or at parturition, although the 
expression of COX-1 mRNA appeared higher at term. Recently, it has been shown that 
levels of COX-2 protein were unaffected by the onset of labour (Sparey et al. 1999) 
As previous reports on the expression of COX-2 in the myornetrium. are conflicting, an 
attempt to measure the level of COX-2 was performed in the human myometriurn with a 
view to addressing the question, "Does the level of COX-2 protein change with gestational 
age or with labour? ". The experiment was then conducted on the myornetrial. tissue lysates 
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from pre-term non-labouring, pKegnant term non-labouring and spontaneous labouring 
women. 
5.1 COX-2 expression 
Using Western blot analysis, COX-2 was found in the human myometrium in all tissue 
groups. As demonstrated in Figure 5.1 A, myornetrial lysates from three different samples in 
each group contained two bands of COX-2 with the molecular masses of 56-60 kD and 
72 kD. This finding is consistent with previous observations (Zuo et aL 1994). Figure 5.1 B 
shows accumulative data from a densitometric analysis, obtained from five pre-term, seven 
term non-labouring and five term labouring myornetrial samples. It was found that there 
were no significant differences in both forms of COX-2 expression among these groups. 
This observation was different from the COX-2 protein level reported by Zuo et al (1994) 
but similar to COX-2 mRNA results as demonstrated recently by Moore et al (1999) and 
COX-2 protein reported by Sparey et al (1999). 
Although the myometrial COX-2 level does not change during pregnancy and 
parturition, particular attention was made to COX-2 as its expression can be regulated by 
cytokines in a variety of cell types (Mitchell et aL 1993; Xu et aL 1997; Diaz et aL 1998). 
In response to IL-1 and TNFcc, the levels of PG in human amnion and myornetrial cells 
increase. This is presumably by the induction of expression of COX-2 (Todd et al. 1996). 
This pathway is known to be involved in the initiation of pre-term. labour. It can be 
proposed that alterations in the levels of this protein and others not involved directly in 
contraction such as oxytocin and TGFP receptors are associated with an increase in 
myometrial activity. By regulating the synthesis of these proteins, which have been 
described as Signalling Associated Proteins (SAPs), the myometrial cells can regulate their 
ability to respond to stimuli and their excitability and contractility. 
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Figure 5.1 'rhe expression of COX-2 in pregnant myornetriurn at 31-35 and 38-40 weeks 
of gestation 
A. Western blots illustrating the expression of' COX-2 in lysates prepared from myometrial 
tissues from pre-term non-labouring (31-35 weeks), pregnant non-labouring (PNL. 38-40 
weeks) and spontaneous labouring myometrium (SL). 
13 illustrates analysis of COX-2 levels in the myometrium. The levels of COX-2 expression 
were determined by densitometry. The values shown are mean + SEM of five samples from 
pre-term. seven samples from PNL and five samples from SL myometrium. 
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Cytokines may play a role in regulating the synthesis of SAPs and CAPs. Cytokine 
stimulation of cellular events is likely to be complex. One cytokine may increase the 
synthesis of a second cytokine, which triggers gene activation. An example of this type of 
interaction has been reported in human osteoblasts (Xu et aL 1997). TNFa increases 
prostaglandin E2 (PGE2) production. However, experiments using an IL-1 neutralising 
antibody, shows that TNFa acts indirectly by stimulating the autocrine production of IL-I 
(Xu et aL 1997). Subsequently, the level of PGE2 increases. In human myometrial cells, IL- 
I and IL-8 increase TPRI expression. In addition, IL-1 and IL-8 increase the synthesis of 
TGF01 and TGF01 can increase the expression of TPRI (see chapter 4). This raises the 
p 'bility that IL-1 stimulates TGFPl, which then activates TPRI expression. Th ossi ere is 
evidence to suggest that TGFP enhances the stimulatory effect of IL- I on PGE2 production 
and the mechanism appears to be mediated primarily by the regulation of COX-2 expression 
(Pilbearn et al. 1997). Tbus, PG production in human myometrial cells in response to IL-1, 
acting by a mechanism presumably dependent on COX-2 synthesis, may also involve an 
intermediate cytokines such as TGFP acting in a 'long range' manner. 
The use of cytokine neutralising antibodies 
The aim of the next study was to investigate the mechanisms regulating the expression 
of TORI and COX-2 in human myometrial smooth muscle cells and to explore the possibility 
of cytokine interactions on the stimulation of TORI and COX-2. Several approaches were 
considered to investigate the possibility that one cytokine may influence the production of 
the second cytokine or its receptor and that the effects seen as a result of the first cytokine 
are mediated via the second. The approaches considered were a) the use of cytokine 
neutralising antibodies or b) the use of antisense ofigonucleotides. In this study, for reason 
of time, the initial approach was to use neutralising antibodies and Western blotting to 
measure the levels of TORI and COX-2 expression. Cytokine neutralising antibodies were 
used to neutralise the effects of endogenous cytokines released following exogenous 
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cytokine stimulation. Chegini et al (1996) has demonstrated that myometrial cells in culture 
can synthesise and release active TGFP I at concentration of approximately of 0.7 nghnl. 
The concentration of TGFP I neutralising antibody used for this study has been calculated 
from the guideline provided by the manufacturer (R&D Systems). It has been shown that 
approximately I pg/ml of the antibody neutralised almost 100 % of the bioactivity due to 
0.25 ng/mI of TGFP L Thus, 3 pg1mI of TGFP I neutralising antibody has been used in this 
investigation. The optimal concentration of the neutralising antibody required would depend 
on the cytokine concentrations, cell types, cell numbers and growth conditions. The 
optimisation was not done in this experiment since the preliminary condition chosen 
demonstrated positive results. Additional work is, however, required to characterise this 
effect. Furthermore, the neutralising antibodies were used with the assumption that the 
specificity and efficacy were that reported by the manufacturer. No independent validation 
was undertaken prior to the experiments. This may lead to a potential problem interpreting 
data when no effect of neutralising antibody was found. However, where a clear change was 
noted it would seem reasonable to assume that the neutralising antibodies were inhibiting 
the proteins. 
5.2 IL-I and IL-8 stimulation of TPRI receptor expression 
Figure 5.2A shows an example of a Western blot examining the expression of TPRI in 
cultured human myornetrial cells. Lane I shows basal levels of TORI expression in non- 
treated cells. Lanes 2 and 4 show the level of TPRI in cells following 24 h treatment with 
IL-1 and IL-8 respectively. The expression of TPRI was increased by exposure to both 
cytokines. We then analysed the levels of TPRI expression from four sets of measurements 
made on cells prepared from four different samples as shown in Figure 5.2B. In order to 
compare measurements between blots, the level of TPRI expression in control cells from 
each blot was set as 100 %. The pooled data showed a significant increase in TPRI levels 
after IL-1 (lane 1) and IL-8 (lane 4) stimulation. The mean values after stimulation were 
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145.75 + 10 % and 153.25 +II% for IL- I and IL-8, respectively (P < 0.0 1). Lanes 3 and 
6 show the levels of expression of TPRI in cells pre-treated with TGFPI neutralising 
antibody for 3h prior to stimulation for 24 h with IL-I and IL-8. Compared to the control 
cells, the levels of TPRI expression were 107.5 + 7.5 % and 102.33 + 14 %, respectively. 
These values are not statistically different from the control level but are significantly 
reduced compared to the levels found in the IL-I and IL-8 treated-cells alone (P < 0.01 and 
P<0.05, respectively). These data suggest that the stimulatory effects of IL- I and IL-8 on 
TPRI expression are indirect and due possibly to their ability to increase myometrial cell 
TGFPI production, which can then act in an autocrine manner. Lane 5 shows data from 
cells pre-treated with IL-I neutralising antibody prior to treatment with IL-8. The mean 
level of expression was found to be 153 + 19 % and significantly greater than basal 
expression (P < 0.01) but not different from the IL-8 stimulated cells. This observation 
shows that IL-8 regulation of TPRI does not involve any co-operative with IL-1. 
Figure 5.2A shows two positively staining bands for theTPRI. There was a weak band 
at more than 65kD and more pronounced band at 60-65kD. The weak bands also appear to 
vary with the treatment of the cells being more pronounced in IL-8 treated cells (lane 4) and 
IL-I(NA) + IL-8-treated cells (lane 5). The nature of the weaker bands is not known. 
However, such a small increase in molecular weight may reflect a biochemical modification 
of the receptors such as glycosylation or phosphorylation. A further characterisation of 
these weak bands was not carried out in the present study. 
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Figure 5.2 The effects of IL-1 and IL-8 on TPRI expression in the presence and absence 
of TGFPI and 11A neutralising antibodN 
A. 'Western blots illustrating the expression of TPRI. The indi%idual lanes sho%%: 1. control 
level of TPRI expression in untreated cells. 2. cells treated with IL-1.3. cells treated %%ith 11- 
I and neutralising antibody to TGFPI. 4. cells treated with ll, -8: 5. cells treated %%ith IL-8 and 
neutralising antibody to IL-1.6. cells treated with IL-8 and neutralistrig antibod% to TGFPI. 
B shows combined analysis of cells from four experiments from 60ur patients. Relatke TPRI 
levels in each group was determined by clensltornetrý. The levels determined for control in 
each blot (lane I) were arbitrarilý set at I O(YVo and the levels of expression in the others 
expressed as a change relative to the control level. The values shown are mean - SUM. 
indicates a significant difference from the control level and represents a significant 
difference from cells treated with either IL-I or IL-8 alone. ý`, P<0.05, ** or ý: ý. P<0.01. 
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5.3 IL-1 stimulation of COX-2 expression 
As shown in Figure 5.3A, stimulation with TGFP 1 (lane 2) had little effect on the level 
of COX-2 expression. In contrast, IL-I stimulated cells expressed higher levels of COX-2 
than those of the control (lane 1) and TGFPl treated cells (lane 4). IL-1 induced COX-2 
expression was reduced by TGFPI neutralising antibody pre-treatment (lane 5). The mean 
levels of COX-2 expression extracted from four batches of cells isolated from four different 
samples are shown in Figure 5.213. Although there was a trend of increasing COX-2 
expression in cells stimulated with TGFPI, the difference was not significant from the 
control level. In contrast, IL- I significantly increased COX-2 expression as shown in lane 4 
by approximately six-fold above the control: an increase to 585.6 ± 82 % (P < 0.001). IL-1 
stimulated COX-2 expression was partially reduced by the pre-treatment of cells with 
TGFP1 neutralising antibody (lane 5). In this experiment, COX-2 expression was 
significantly increased to 375.12 ± 41 %. This level was significantly greater than the 
control (P < 0.01) and significantly smaller than for cells treated with IL-1 alone (P < 0.05), 
indicating that TGFPI is involved in the process of IL-I-stimulated COX-2 expression. 
These observations also suggest that IL- I can independently stimulate COX-2 expression in 
human myornetrial cells. 
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Figure 5.3 The effects of IIA and TGFPI on COX-2 expression in the presence and 
absence of TGFO neutralising antibod% 
A. Western Hot,, illustrating the expression of COX-2. The individual larws sho,. %: 1. the 
control level of expression in untreated cells. 2. cells treated with l'GFP 1.3. cells treated %%ith 
TGFP I in the presence of I L- I neutralising antibody. 4. cells treated %% Ith I L- 1.5 - cells treated 
with IL- I and TGFO I neutralising antibody. Neutralising antibodies %%ere added 3h prior to 
cytokine addition and were presented throughout cytokine stimulation for 24 h. 
B. Combined analysis of cells from 4 separate experiments from four different patients. The 
levels of COX-2 expression were determined by densitometr-%. The values sho-wn are mean 
SEM. * indicates a significant difference from the control level and represents a significant 
difference from cells treated with I L- I alone. ý. P<0.05, P<0.0 1. P -- 0.00 1. 
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5.4 Discussion 
At term the myometrium is primed for parturition by increasing the expression of 
proteins essential for cell signalling, SAPs, and contraction, CAPs. COX-2, a regulatory 
enzyme in the mechanism of PG synthesis, is another example of SAPs whose levels 
increase with gestational age and decrease with labour (Zuo et aL 1994). In the present 
study it was found that COX-2 in the myometrium was expressed in two bands at 
approximately 56-60 W and 72 kD as previously reported by Zuo et aL (1994). Our finding 
that the expression of myometrial COX-2 protein did not change either during pregnancy or 
during labour was similar to the pattern of COX-2 mRNA and protein expression 
demonstrated recently (Moore et aL 1999; Sparey et al 1999). In contrast, the COX-2 level 
in this study was different from the previous report that COX-2 expression was decreased at 
the onset of labour compared to that in non-labouring myometrium (Zuo et aL 1994). The 
reason for this difference is unknown. The previous observation was based on 
immunohistochemistry in which the scoring was considered qualitative but on Western 
blotting analysis in this investigation, which relies upon densitometric scanning and state. It 
has been shown that myometrial samples taken from different regions revealed different 
trends of COX levels. For instance, the level of COX increased significantly from the uterine 
fundus toward the lower segment and from outer to inner layer (Keirse et aL 1985, Sparey 
el al, 1999). Thus, it is likely that a topographic difference of expression may occur in the 
myometrium and account for the difference in COX-2 expression. It must be borne in mind 
that PG is not stored and is produced when needed, and the half-life of COX is short 
(Meade et aL 1993). Therefore, an increase in expression of this enzyme may be transient 
and can not be easily detected if the myometrium is not sampled at the appropriate time. 
Little is known about the mechanisms by which SAP and CAP genes are activated in 
myometrial smooth muscle during late pregnancy. However, the findings from chapter 4 
suggest that IL-I and IL-8 can regulate TPRI expression, which is a SAP. There is also 
indirect evidence to suggest that other SAPs may be regulated by cytokines. For example, 
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IL- I has been found to increase PG synthesis in myometrial cells probably by increasing the 
expression of COX-2 (Todd et aL 1996). The data observed in this study show that IL- I 
increased the expression of COX-2 in myometrial smooth muscle. This observation raises 
the possibility that IL- I could activate genes for TPRI and COX-2 by the same intracellular 
pathway. However, the results suggest that this is not the case and more complex cytokine 
interactions are involved in regulating SAPs expression. 
Several types of cytokine interaction have been identified in myornetrial smooth muscle. 
Firstly, there may be direct effects, which do not require other cytokines or proteins in the 
mechanism of action. Examples of this type of interaction may include the stimulation of 
TPRI by TGFP I and the reduction in IL-8 receptor expression by IL-8 as shown in the 
previous chapter. These examples illustrate positive and negative feedback role of 
cytokines. 
Secondly, the IL-1 stimulation of TPRI illustrates a 'long range' interaction of 
cytokines. It has been shown in chapter 4 that IL-I and IL-8 can increase the production of 
TGFP I in human myometrial smooth muscle cells in vitro. In addition, TGFP I can increase 
the expression of TPRI. The data from the present study suggest an indirect effect of IL-1 
and IL-8 on TPRI expression. The data show that IL-1 and IL-8 stimulation of TPRI is 
completely inhibited by TGFPI neutralising antibody, suggesting that the mechanism of 
action is mediated exclusively by the sequential production and autocrine action of TGFP I. 
It has been hypothesised that a cytokine cascade is involved in the mechanism of normal 
labour whereby cytokines are produced in a specific sequence. The observations in this 
study support this hypothesis and demonstrate that in response to IL-1 and IL-8, TGFP1 is 
the next cytokine to appear in the sequence of a cytokine cascade in the myometrial cells. 
The experiments also show that the action of IL-8 is not mediated via the stimulation of IL- 
1. Therefore it would appear that two cytokines, IL-1 and IL-8, have the same action. The 
possible synergistic and complex interplay between IL-1 and IL-8 and their effects on TORI 
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expression has yet to be elucidated. Other examples of this type of cytokine interaction may 
include TNF stimulation of PGE2 production via IL- I in human osteoblast-like cells (Xu et 
aL 1997). 
Thirdly, cytokine interaction may involve a synergistic interplay between cytokines. In 
the experiment presented here, IL-I can induce COX-2 expression in myometrial cells, 
which is consistent with the observation by Hertelendy et al (1999). TGFP I does not appear 
to stimulate this enzyme although a minor increase in the stimulation is observed. However, 
TGFP I acts in conjunction with IL- I to promote the activation of COX-2 expression. There 
are many examples of this synergistic action in the literature (Xu et aL 1997; Diaz et aL 
1998). TGFP, TNF and IL-1, for example, combine to stimulate PGE2 production in 
osteoblast-like cells and in human lung fibroblasts (Xu et aL 1997; Diaz et aL 1998). 
TGFP1 alone has no effect on COX-2 expression but the addition of TGFPI increases the 
IL-I or TNFa stimulation of COX-2 mRNA and protein in human lung fibroblast cells 
(Diaz et aL 1998). The action of TGFP in lung fibroblasts appears to be via the stabilisation 
of COX-2 mRNA after the increase in transcription activated by IL-I (Diaz et aL 1998). 
Overall, a sequential process of cytokine synthesis with autocrine action and a synergistic 
action between cytokines occurs in myometrial smooth muscle cells in vitro. 
In addition to interactions between cytokines, the possibility exists that a cytokine may 
activate a different signalling system, which may then have an effect on the cells. For 
example, the data presented here show that IL-1 increases TPRI expression. IL-1 also 
stimulates the production of COX-2 and the release of PG. Thus, the IL-1 induced changes 
in TORI expression could be mediated via PG. This idea could be examined directly using an 
inhibitor of COX-2 to remove any effect of increase PG. This was not done in the present 
study. Indirect evidence suggests that such an interaction may not occur in the myometrium. 
Prostaglandin can stimulate cAMP formation (LopezBernal et al. 1991; Europe Finner et al. 
1994) and cAA4P dramatically reduced TORI expression (see chapter 6). Thus, the action of 
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prostaglandin, mediated through MAP, would be predicted to give an opposite result to 
that observed. 
In conclusion, these in vitro results may illustrate the complexities of an autocrine- 
signalling cascade within the myometrial smooth muscle in the physiological process of the 
maturation of myometrium. It would appear that the autocrine cascade regulates the 
expression of specific SAPs. Specific cytokines may also be the primary activators of SAP 
and CAP expression. IL-1, for example, is the primary activator of COX-2 while TGFPI is 
the primary activator of RyR2 (Awad et aL 1997) and TPRI. In addition to operating at the 
level of gene expression, cytokines may also influence the post-translational regulation of 
proteins. If this idea is correct and individual cytokines are dominant at different stages in 
the cascade then different SAPs and CAPs Will appear at different times in late pregnancy. 
The synergistic actions of cytokines may further fine-tune the expression of SAPs and 
ultimately the expression of CAPs. Consequently, the development of contractility occurs 
within the myometrium at term in preparation for parturition. 
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Chapter 6 
Effect of raised cAMP on TGFPI and TORI Expression in human 
myometrial cells in vitro 
The mechanisms regulating SAP and CAP expression are poorly understood. From our 
previous study, a complex cytokine-signalling cascade has been suggested to be involved in 
this mechanism in the latter stages of pregnancy. TGFPI and TGFP receptors are part of 
this cytokine-signalling cascade in myornetrial smooth muscle cells. Factors regulating the 
expression of TGFPI and TPRI are not clearly understood but, at least in part, involve 
other cytokines such as IL-I and IL-8 and sex steroid hormones as described in the previous 
chapters. 
It has been recognised that progesterone is important for maintaining myometrial. 
quiescence throughout pregnancy (Liu & Rebar, 1999). Progesterone acts through a 
number of mechanisms including inhibition of prostaglandin production and CAP synthesis 
(Able et aL 1980; Lye, 1996). Genes encoding for proteins that are involved in cANT 
production have been known to regulate myometrial quiescence in mid-pregnancy and 
myometrial contraction at term (Europe Finner et aL 1993,1994). cANT activates protein 
kinase A to promote smooth muscle relaxation (Sanborn et al. 1998). cANT has been 
shown to be involved in the regulation of gene expression for example TGFP I in pituitary 
and choriocarcinoma cells (Ritvos & Eramaa, 1991; Pastorcic & Sarkar, 1997) and 
prolactin (Peers et al. 1991). A role for cANT in gene regulation in human myometrial 
smooth muscle cells has yet to be established 
It can be speculated that changes in the level of cANT may be involved in triggering or 
modulating the autocrine-signalling cascade in the myometriurn during pregnancy. In this 
study the effects of increasing cANT by forskolin, an activator of adenylyl cyclase, on the 
expression of TGFP I and TPRI were determined in order to examine this hypothesis 
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6.1 Forskolin effect on cAMP levels in myometrial cells in vitro 
The first series of experiments were done to confirm that exposing human myometrial 
cells to forskolin resulted in an elevation in the level of intracellular cANT. Figure 6.1 (inset 
within the main panel) shows the response of three individual cells isolated from three 
different subjects (performed in triplicate). Although it was noted that there were 
differences in responses to forskolin in individual batches, their responses were similar in 
trend when compared to those of control cells. As shown in the main panel, treatment of 
cells with forskolin (5 pNl) for 24 h slightly increased cANT from a basal level of 1.68 + 
0.89 to 26.19 + 7.84 frnol/pg protein (P < 0.05). Treatment with forskolin for 48 and 72 h 
did not result in a significant rise in cANT: 11.22. + 5.25 and 7.34 + 3.21 fmol/pg protein 
respectively. Thus, the effect of prolonged forskolin treatment on the elevation of 
intracellular cANT is transient. The present data show that after 24 h of forskolin treatment, 
cAMP still remains elevated. The effect of forskolin treatment on TGFP receptor is clear 
(see the next section). However, the precise time at which the elevated cAW interacts with 
the genome to produce this effect can not be discerned from the present experimental 
protocol. This, however, does not detract from the observation of the profound effect on 
the TGFP receptor expression. A decrease in the levels of cANW after 48 and 72 h may 
reflect the down regulation of adenylyl cyclase during prolonged stimulation or the 
degradation of cAW by phosphodiesterase as no enzyme inhibitor was applied in this 
experiment. 
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Figure 6.1 Elevation of intracellular cANIP by forskolin 
Confluent human myometrial, smooth muscle cells were cultured in the presence of forsk-olin 
(5ýLý and without forskolin for the indicated time (C, control at 24 h). Following the treatrnentý 
cAW content in the cells was measured using cAMP enzymc-immunoassay. The data shown in 
an inset panel is the data from three different experiments performed in triplicate on cells fron, 
three myometrial samples. The data shown in the main panel arc the mean data from three 
samples. Values at each time point are mean + sEm and expressed as f=Vpg protein. *, P<0.01 
as compared to the control. 
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6.2 Forskolin effect on TGFfll and TflRi expression 
Figure 6.2 shows data obtained using ELISA to measure the total levels of TGFPI in 
the supernatant of control cultures and cells exposed to forskohn for progressively longer 
periods of time. The steady state levels of TGFP1 production were increased significantly 
from control levels of 23.53 + 0.61 pg/pg protein to 29.89 + 1.08 pg/ýLg protein at 72 h of 
treatment. At 24 and 48 h there was no significant difference in the total level of TGFP I in 
cells treated with forskolin compared to the control cells. Since cAMP is not elevated at 
72 h, it is doubtful that the small increase represents a true response. 
The effects of prolonged exposure to forskolin on TPRI appeared more complex than 
the stimulation of TGFPI. Figure 63A shows an example of a Western blot illustrating 
TPRI expression in one batch of cells. The level of expression in control cells is shown in 
lane 1. This level was arbitrarily set to 100 % in order to compare the levels of expression in 
the treated cells. Exposing cells to forskolin for 24 h reduced TORI expression (lane 2). 
After 48 or 72 h the levels of expression were greater than the level measured at 24 h and 
did not appear to be significantly different from control levels (lanes 3 and 4). Figure 63B 
shows mean data from five separate experiments on five batches of myornetrial cells. 
Raising cAMP for 24 h decreased TORI expression significantly to 9.7 + 2.29 % compared 
to control levels (P < 0.00 1). With 48 and 72 h treatments TORI expression was 74 + 
14.51 % and 102.6 + 10.14 % compared to control levels. The levels of expression at 48 
and 72 h were significantly greater than at 24 h but did not appear to be significantly 
different from the control level. 
101 
Figure 6.2 The effect of forskolin on TGFPI levels 
Confluent human myornetrial smooth muscle cells were cultured in the presence of forskolin 
(5ttM) and without forskolin for the indicated time (C, mean data of control at 24,48 and 
72 h). Following the treatment the total concentration of TGFP I in the culture medium %N-as 
measured using ELISA. Values are mean + SEM of four experiments from four different 
tissues assayed in duplicate (n = 4) and expressed as pg/pg protein. P<0.0 1 as compared 
to the control. 
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Figure 6.3 The effect of forskolin on the expression orTPRI 
Myometrial smooth muscle cells (40 pg) from control (C) and cells treated with forskolin 
(5pM were separated in 7.5 % SDS-PAGE and subjected to NVestem blot analysis with 
antibodies to TPRI. A shows an example of TPRI expression in cells: control at 24 h (lane 1), 
forskolin treated cells for 24,48 and 72 h (lane 2,3 and 4, respectively). 
B illustrates analysis of five'experiments isolated from five different samples (n = 5). Relative 
TPRI levels in each blot were determined by densitometry. The levels determined in each blot 
for the control cells were arbitrarily set at 100% and the levels of expression in the forskolin 
treated cells expressed as a change relative to the control level. The values shown are mean + 
SEM. ***, P<0.001 as compared to the control; P<0.01; P<0.001 as compared to 
treated cells at 24 h. 
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Results 
6.3 The effects of TGFfll on Ga. and Gail, 2expression 
The data are consistent with the operation of a signalling cascade with cAMP feeding 
forward to regulate the expression of TPRI. In late pregnancy during labour the expression 
of the G-protein (Ga, ), which regulates adenylyl cyclase and cAMP levels, is decreased 
(Europe Finner et aL 1994). With such a sequence of signalling events, it is possible that 
TGFP I in the myometriurn might feed back on the cAW system by affecting the ability of 
the smooth muscle cells to produce cANT. Therefore, a series of experiments was carried 
out to determine the effect of exposing myornetrial cells to TGFP I (I nghnl) for 24 h on the 
expression of G protein sub-units that stimulate and inhibit adenylyl cyclase activity. 
Figure 6AA illustrates examples of Western blots showing the levels of Ga. detected at 
45 kD and Gal, 2 at 41 kD respectively in control cells and cells treated with TGFPI. Figure 
6AB shows mean data from densitometric scans of the Western blots from five preparations 
of cells from different patients for Ga. and four preparations for Gccil, 2. There was no 
significant change in the expression of both Ga. and GajI, 2 in the TGFP I treated cells. Thus, 
there is no evidence for a feedback mechanism of TGFPI on G-proteins under these 
conditions. 
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Figure 6.4 The effects of T(; Fpl on the expression of G(i, or 
A illustrates examples Western blots shoý%ing the le%el,, of Gj, and Ga, j -, In control cells 
and cells treated with TGFP1 H n&,, ml) for 24 h. B sho%%s mean data - SEM from 
densitometric scan of the Westem blots from fi%e preparations of cells from different 
patients for Gcx, (n = 5) and four preparations from four different hatches for G(x,,., (n: 
The values shown are expressed in arbitrar-, - unit. 
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6.4 Discussion 
The present study has been carried out in a timescale from 24 h to 72 h. The fact that 
the cANP is not elevated at 48 and 72 h after forskolin treatment means that is difficult to 
interpret the consequences of the treatment. For this reason the discussion of the data 
derived from 24 h treatment is considered to be more relevant. The results confirm that 
treatment with forskolin for periods up to 24 h causes an increase in cAND levels. 
Expression of TPRI was decreased after 24 h of treatment with forskohn. Thus, the 
expression of TPRI appears to be regulated by cAMP such that an elevated cAND level 
reduces its expression. 
In contrast, an elevation in cAND at 24 h does not affect the production of TGFP1. It 
can be suggested that the mechanisms regulating the expression of the cytokine and its 
receptor are different. The difference in the regulation of the cytokine and its receptor may 
represent an important step in determining the overall responsiveness of the myometriurn in 
vivo. The nature of the intracellular pathways regulating expression of the elements of the 
TGFP system in myometrium remains to be identified. 
The mechanisms by which cAMP modulates myometrial cell TORI are not known. 
Most cAMP-mediated genes contain cAMP-responsive elements (CRE) that are recognised 
by CREB transcription factor (Borrelli et aL 1992; Lalli & Sassone-Corsi, 1994). To date 
there is no data available about CRE on the TPRI promoter. However, study by Bloom et al 
(1996) indicates that the human TPRI promoter contains the SpI binding sites. cAMP has 
been shown to modulate transcription factor SpI in leukaemia cells (Rohlff et aL 1997). 
Therefore it is possible that cAMP may modulate the activity of transcription factor SpI 
that binds to the SpI binding sites on the TPRI promoter. This may result in decreased 
TpRI expression at 24 h as shown in this study. The transient reduction of TPRI expression 
may also result from post-transcriptional mechanisms such as the stabilisation of mRNA or 
enhanced receptor degradation. 
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It has been reported that an increase in Ga. expression in human myornetriurn during 
gestation favours myornetrial relaxation by increasing agonist-induced cANV production 
(Europe Finner et aL 1993). A decrease in this G-protein sub-unit may trigger the 
mechanism for initiation of labour (Europe Finner et aL 1994). Although cAMP has been 
proposed to dominate the quiescent phase of pregnancy, the intraceflular levels of cANW 
have not been measured directly. As term approaches the relaxing actions of exogenous 
isoproterenol stimulated adenylyl cyclase decrease without any change in enzyme activity 
stimulated by forskolin. This may be the result of a decrease in Ga, coupling to adenylyl 
cyclase towards term (Litime et aL 1989) or a decrease in the expression of P-adrenergic 
receptors at the end of pregnancy (Breuiller et aL 1987). This event may lead to a decrease 
in cANT production. During pregnancy, the level of Ga, expression in myornetrium. 
changes but not the level of adenylyl cyclase (Europe Finner et aL 1994). Taken together 
these observations suggest that any regulation of cANT may be at the level of agonist 
concentrations or the expression of membrane receptors coupled to G protein rather than 
the changes in adenylyl cyclase levels. 
In this study, the reciprocal situation does not appear to occur, in which TGFPI does 
not have any regulatory influence of the expression of G-protein sub-units that regulate 
cAW production. Therefore, it can be suggested that there is not a negative feedback from 
TGFPI to decrease G protein expression in cultured myornetrial smooth muscle cells and 
possibly in the myometrium in vivo. 
In summary, the present study demonstrates the cAMP-induced decrease in TPRI 
expression in the rnyometrial smooth muscle cells. The significance of this observation is not 
clearly understood. cAMEP favours myometrial relaxation during pregnancy and TGFP I has 
been reported to be involved in the regulation of CAP. Based on these assumptions, it is 
possible that increased cAAV during early and mid pregnancy may reduce the 
responsiveness of cells to TGFP1 and that results in maintaining myornetrial quiescence. It 
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is clearly that further study of functional consequence of the observed change in TORI 
expression may lead to better understanding in the physiological role of TGFP I system in 
the myometriurm 
/ 
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Chapter 7 
CONCLUSIONS 
In the aim of this thesis the foRowing hypotheses were proposed 
1). 'that TGFfll and TGFfl receptors are present in the myometrium at term. 
2). 'that expression changes with gestation. 
The results show that TGFP I and TGFP receptors are present in the myometrium at term, 
confirming the first hypothesis. The expression of TGFP I does not change dramatically with 
gestation. However, TGFP receptor expression changes with gestation, supporting the 
second hypothesis. 
The results obtained from this study have shown that TGFPI and TPRI can be 
modulated by cytokines, sex steroids and cAW. This demonstrates that regulation of 
TGFP1 and its receptor in myometrial cells and possibly in the myometrium in vivo is 
complex. In addition, the fact that myometrial cells can produce TGFPI, suggests an 
autocrine role in the myometriurn. The finding that the expression of the cytokine receptors 
changes with pregnancy has led us to introduce the concept of signalling-associated proteins 
(SAPs). The SAPs are responsible for the regulation of other SAPs that trigger the 
expression of CAPs. This introduces the further concept of autocrine, cytokine interaction in 
the myometrium leading to the preparation of myometrium for term. 
The onset of labour begins when SAPs and CAPs are in place at the right time. If SAPs 
and CAPs are expressed before term, this may lead to myometrial activation resulting in 
premature delivery. If SAPs and CAPS are not in place, successful labour will be unable to 
proceed. TGF01 and TPRI are SAPs and TGFPI is known to up-regulate RyR2 in 
myometrial cells. It is known that TGFPI can induce gene expression through TPRI 
activation. Thus, the functional role of TGFP I as a direct stimulator for other CAPs has yet 
to be elucidated. The importance of TGFPl in human parturition, apart from being a CAP 
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stimulator, has also been suggested in the literature. For example, Casey & MacDonald 
(1997) suggested that TGFPI acts in myometrial cells to negate some actions of 
progesterone on the expression of myometrial Cx-43 and endothelin-1. This idea shows an 
alternative mechanism of progesterone withdrawal, which is not present in human 
pregnancy. 
In this thesis, cultured myometrial cells maintained in fetal calf serum have been used. 
Cultured cells have both advantages and disadvantages. The disadvantages are that culture 
model is an isolated system and consequently the environment of the cells must be provided 
by the experimenter. In consequent the choice of the media is inevitably arbitrary. In 
addition, as a consequence of cells being in vitro they are prone to differentiation and 
phenotypic change that might not represent cells in vivo. However, cultured cells allowed us 
to manipulate the environment, which can not be done in humans, to obtain information 
regarding how the cells are regulated. 
From the overall observations in this thesis, the following model (Figure 7.1) for the 
regulation of TPRI, leading to preparation of human myornetriurn can be proposed. 
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Oestrogen IL-1, IL-8 TGFol cAMP 
Progesterone 
TGFP receptor type I 
Synthesis Contractile Onset of 
of CAPs responsiveness labour 
Myometrial quiescence 
Myometrial Active 
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Figure 7.1 Proposed model for the preparation of the human myometrium 
Conclusions 
Directions for future work 
1. To determine the time course of other cytokines and cytokine receptors during the last 
trimester of pregnancy. 
2. To identify interactions between cytokines which act as signalling-associated proteins and 
steroid hormones on the expression of other CAPs such as Cx-43 and Caý+ channels. 
3. To identify the signalling pathways of TGFPI which affects the expression of TPRI 
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0 ppen ix 
reviation 
AT-1 Activator protein-1 
BSA Bovine serum albumin 
[Ca2+jj Intraceffular free calcium concentration 
cAMP Adenosine 3'5'-cychc monophosphate 
CAIP Contraction Associated Protein 
COX-2 Cyclooxygenase-2 
Cx-43 Connexin-43 
DAB Diaminobenzidine 
EDTA Ethylenediamenetetraacetic acid 
ELISA Enzyme linked immunosorbent assay 
FCS Foetal calf serum 
G-protein Guanine nucleotide binding protein 
HBSS Hanks balanced salt solution 
HEPES N-2-hydroxyethylpiperazine-N-2-ethan- 
sulphonic acid 
HRP Horseradish peroxidase 
H-ei Interleuldn-I 
IIIA Interleukin-8 
IL-1RI Interleukin- I receptor type I 
II, -8RB Interleukin-8 receptor type B 
kD Kilodalton 
mRNA Messenger ribonucleic acid 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PG Prostaglandin 
RyR Ryanodine receptor 
SDS Sodium dodecyl sulphate 
SEM Standard error of the mean 
SAP Signalling Associated Protein 
TBS Tris buffered saline 
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TGFP 
TORI 
TPRII 
TPRIH 
Tris 
Transforming growth factor beta 
TGFO receptor type I 
TGFO receptor type II 
TGFO receptor type III 
2-amino-2-(hydroxymethyl)-1,3-propandioI 
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0 Appendix 2 
List of suppliers 
Amersham Life Science Ltd. 
Amersharn Place, 
Little Chalfont, 
Bucldnghamshire, 
BP79NA 
Tel 0800 515313 
Bio-Rad lAboratories 
Bio-Rad House, 
Mayland Avenue, 
Hemel Hempstead, 
Hertfordshire, 
HP2 7TD 
Tel 0800 181134 
Dako Ltd. 
Denmark House, 
Angel Drove, Ely, 
Cambridgeshire, 
CB74ET 
Tel 0135 366 9911 
Insight Biotechnology Ltd. 
PO Box 520, 
Wembly, 
Nfiddlesex, 
HA97YN 
Tel 0181385 0303 
MEN"' Life Science Products, Inc. 
UK 
Tel 0800 896046 
R&D Systems Europe Ltd. 
4-10 The quadrantý 
Bartaon Lane 
Abingdon 
OX14 3YS 
Tel 0123 555 1100 
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Schleicher & Schuell UK Ltd. 
Unit 11, Brunswick Park Industrial Estate, 
London, 
NI I lJL 
Tel 01813613 111 
Sigma-Aldrich Company Ltd. 
Fancy Rd, 
Poole, 
Dorset 
BH12 4QH 
Tel 0800 717181 
Whatman International Ltd. 
Whatman House, 
8t Leonard's Rd, 
20/20 Maidstone, 
Kent, 
NEI 8 OLB 
Tel 0162 267 4821 
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Appendix 3 
Solution compositiom for SDS-PAGE 
Acrylamide gel, 30 % 
Separating buffer 
Stacldng buffer 
Gel running and clectrophoresis 
Formulation for separating gel (7.5 %) 
Acrylanýde gel 
Separating buffer 
Distilled water 
Ammonium persulfate (IS mgln-J) 
Formulation for stacking gel (5 %) 
Acrylatnide gel 
Stacking buffer 
Distilled water 
TEMED 
Ammonium persulfate (15 mg/ml) 
Solution composition for transfer buffer 
Transfer buffer (10 x) 
30 g acrylamide, 0.36 g bis-acrylamide in 100 
ml distiHed water 
1.5 M Tris base, pH 8.8 and 0.4 % SDS 
(adjust pH with HCI) 
0.5 M Tris base, pH 6.8 and 0.4 % SDS 
(adjust pH with HCI) 
25 mNI Tris base, pH 8.6,192 mM Glycine 
and 0.1 % SDS 
2.2 ml 
2.25 ml 
4.03 n-d 
7.5 td 
225 W 
0.84 ml 
1.25 ml 
2.75 ml 
5W 
125 
0.25 M Tris base, pH 8.6 and 1.92 M 
Glycine 
Fonnulation for working transfer buffer (100 ml) 
Transfer buffer (10 x) 10H 
Methanol 20 n-d 
Distilled water 70 ml 
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Appendix 4 
Components of TGF01 assay system 
Micro-titre plate 
Detection antibody 
Biotinylated second antibody 
Streptavidin-IIRP conjugate 
Standard 
Standard reconstitution reagent 
Assay buffer 
Wash buffer 
PBS tablet 
96 wells coated with mouse anti-TGFO I 
rabbit antibody against TGFP 1,75 gl 
anti-rabbit Ig conjugated to biotin, 50 pl 
streptavidin conjugated to horseradish 
peroxidase 
recombinant TGFO I in an acid/gelatin buffer, 
which give 21 ng/mI after reconstitution 
2H of 4 mM HCI and 0.1 % BSA 
15 ml of concentrate buffer, when diluted 
with PBS (1: 10), gives 0.01 M PBS, pH 7.4 
containing 0.1% BSA (w/v) 
15 ml. of concentrate buffer, when diluted 
with PBS (I: loo), gives 0.01 MPBS, pH 7.4 
containing 0.2 % (v/v) Tween-20 
0.01 M PBS, pH 7.4 (one tablet dissolved in 
200 n-A of distilled water) 
TMB substrate 3,3', 5,5'-tetramethylbenzidine/hydrogen 
peroxide solution in 20 % (v/v) 
dimethylformainide, 22 n-d 
Stop solution 0.19 M sulfuric acid, 12 ml 
Reagents for sample activation 
IM HCI (100 ml) add 10 ml of concentrated (10 M) HCI to 90 
ml of distilled water 
1.2 M NaOI-1/0.5 M BEPES (100 n-A) 4.8 g NaOH dissolved in 75 n-A of distilled 
water. Add 11.9 g of BEPES and adjust 
volume to 100 H with distilled water 
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Components of cAMP assay system 
Micro-titre plate 96 wells coated with donkey anti-rabbit IgG 
Assay buffer 0.05 M sodium acetate buffer, pH 5.8 
containing 0.02 % BSA and 0.01 % 
preservative 
Standard (for non-acetylate assay) cAW standard, on reconstitution gives 32 
pmol cAW/mI 
Antibody Rabbit anti-cAW 
Peroxidase conjugate cANT-horseradish peroxidase 
Wash buffer concentrate on dilution give 0.01 M PBS, pH 7.5 
containing 0.05 % Tween-20 
TNIB substrate 3,3', 5,5'-tetramethylbenzidine/hydrogen 
peroxide solution in 20 % dimethyformamide 
Lysis reagent 1 2g dodecyltrimethylammonium bromide 
Lysis reagent 2 5g of solid contain no hazardous chemical 
Reagent preparation (all reagents were equilibrated to room temperature before used) 
Assay buffer dilute with 500 ml of distilled water 
Lysis reagent IA dissolve 2g of lysis reagent I in 80 ml of 
assay buffer 
Lysis reagent IB take 10 ml of lysis reagent IA and make up 
to 100 ml with assay buffer 
Lysis reagent 2A dissolve 5g of lysis reagent 2 in 100 ml of 
assay buffer 
Lysis reagent 2B take 10 H of lysis reagent 2A and make up 
to 40 ml with assay buffer 
Standard reconstitute in 2 n-A of lysis reagent 1B, the 
final solution contains 32 pmol cANV/n-d 
Antiserum dilute with IIH of lysis reagent 2B 
cAW peroxidase conjugate dilute with II n-A of assay buffer 
Wash buffer dilute with 500 ml. of distilled water 
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